

Comprehensive genotype-phenotype analysis in POLR3-related disorders

Mackenzie A. Michell-Robinson,^{1,2} Stefanie Perrier,^{1,2} Samuel Gauthier,^{2,3} Alexa Derksen,^{1,2} Quentin Sabbagh,^{1,2} Mathias Girbig,^{4,5} Agata D. Misiaszek,^{4,6} Amy M. Pizzino,⁷ Deborah L. Renaud,⁸ Danilo De Assis Pereira,^{9,10} Paola Okuda,¹¹ Luciana Maestri Karoleska,¹² Stephanie Keller,¹³ Karen Chong,¹⁴ Laurence Gauquelin,¹⁵ Bernard Brais,^{1,3} Barbara Leube,¹⁶ Tiffany Grider,¹⁷ Michael E. Shy,¹⁷ Rebecca Schüle,^{18,19,20} Martina Minnerop,^{21,22,23} Enrico Bertini,²⁴ Francesco Nicita,²⁴ Davide Tonduti,^{25,26,27} Christoph W. Müller,⁴ Adeline Vanderver,^{28,29} Nicole I. Wolf,^{30,31} and Geneviève Bernard^{1,2,3,32,33,34,*}

Summary

RNA polymerase III (RNA Pol III)-related disorders (POLR3-RDs) are a group of clinical entities characterized by causal variants in genes encoding RNA Pol III subunits, including *POLR3A*, *POLR3B*, *POLR1C*, *POLR1D*, *POLR3D*, *POLR3E*, *POLR3F*, *POLR3GL*, *POLR3H*, and *POLR3K*. These typically cause developmental phenotypes affecting the central nervous system; the eyes; connective tissues including bones, teeth, and endocrine axes; and the reproductive system. Similar phenotypes can be caused by variants in separate subunit genes (multigenic). In contrast, variants in the same gene can cause different phenotypes (pleiotropy), making genotype-phenotype correlation challenging. POLR3-RDs, though individually rare, have never been analyzed collectively. To bridge this gap, we developed an extensive database encompassing all published and unpublished cases of POLR3-RDs and conducted the first comprehensive genotype-phenotype correlation study across their entire spectrum. This work contributed new cases, representing 13% of all documented cases in the literature, along with 31 novel variants, accounting for 8% of all identified variants. This database was constructed by systematically reviewing the literature and integrating data from patients under the care of our international network of collaborators. The dataset includes genotype curation, bioinformatics, prior publications, and individual patient outcome information. By leveraging these comprehensive data, we were able to establish clear genotype-phenotype correlations for some pathogenic variants, which will help provide optimal clinical care and genetic counseling (including insights into disease phenotypes and progression) and offer valuable guidance for future clinical trial design and patient stratification.

RNA polymerase III (RNA Pol III)-related disorders (POLR3-RDs) are a group of clinical entities characterized by pathogenic variants in genes encoding Pol III subunits, including *POLR3A*, *POLR3B*, *POLR1C*, *POLR1D*, *POLR3D*, *POLR3E*,

¹Department of Neurology and Neurosurgery, McGill University, Montréal, QC H4A 3J1, Canada; ²Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC H4A 3J1, Canada; ³Department of Human Genetics, McGill University, Montréal, QC H4A 3J1, Canada; ⁴Molecular Systems Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany; ⁵Evolutionary Biochemistry Group, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany; ⁶Genome Regulation Group, Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland; ⁷Neurology Department, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; ⁸Department of Neurology, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA; ⁹Department of Pediatric Neurology, Pontifical Catholic University of São Paulo (PUC-SP), São Paulo 18030-070, Brazil; ¹⁰Department of Pediatric Neurology, University of Campinas (UNICAMP), Campinas, São Paulo 18030-070, Brazil; ¹¹Psychiatry and Medical Psychology, Federal University of São Paulo (UNIFESP), São Paulo 5445030, Brazil; ¹²Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo 5445030, Brazil; ¹³Division of Pediatric Neurology, Pediatrics Department, Emory University, Atlanta, GA 30329, USA; ¹⁴Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1Z6, Canada; ¹⁵Division of Pediatric Neurology, Department of Pediatrics, CHUL et Centre Mère-Enfant Soleil du CHU de Québec-Université Laval, Québec City, QC G1V 4G2, Canada; ¹⁶Institute of Human Genetics, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; ¹⁷Department of Neurology, University of Iowa Health Care Medical Center, Iowa City, IA 52242, USA; ¹⁸Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany; ¹⁹German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany; ²⁰Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL 33136, USA; ²¹Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, 52425 Jülich, North Rhine Westphalia, Germany; ²²Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty & University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, North Rhine Westphalia, Germany; ²³Department of Neurology, Center for Movement Disorders and Neuromodulation, Medical Faculty & University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, North Rhine Westphalia, Germany; ²⁴Hospital Center for the Care and Treatment of Leukodystrophies and Associated Conditions (COALA), 20154 Milan, Lombardy, Italy; ²⁵Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children's Research Hospital IRCCS, 00165 Rome, Lazio, Italy; ²⁶Division of Child Neurology, Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, 20154 Milan, Lombardy, Italy; ²⁷Pediatric Neurology Unit, Vittore Buzzi Children's Hospital, 20154 Milan, Lombardy, Italy; ²⁸Division of Neurology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; ²⁹Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; ³⁰Amsterdam Leukodystrophy Center, Department of Child Neurology, Emma Children's Hospital, Amsterdam UMC, 1081 HZ Amsterdam, the Netherlands; ³¹Amsterdam Neuroscience, Amsterdam UMC, VU University, 1081 HZ Amsterdam, the Netherlands; ³²Department of Pediatrics, McGill University, Montréal, QC H4A 3J1, Canada; ³³Department of Specialized Medicine, Division of Medical Genetics, Montreal Children's Hospital and McGill University Health Centre, Montréal, QC H4A 3J1, Canada

³⁴Lead contact

*Correspondence: genevieve.bernard@mcgill.ca
<https://doi.org/10.1016/j.xhgg.2025.100481>.

© 2025 The Authors. Published by Elsevier Inc. on behalf of American Society of Human Genetics.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



POLR3F, *POLR3G*, *POLR3GL*, *POLR3H*, and *POLR3K* (see [Tables 1](#) and [S1](#)).^{1–191} RNA Pol III is a constitutively expressed seventeen-subunit polymerase enzyme complex responsible for the transcription of essential non-coding RNAs involved in transcription, RNA processing, and translation (see Zhou and Van Bortle, 2023).^{192–195} Canonical RNA Pol III transcripts include the entire pool of tRNAs and 5S ribosomal RNA, essential for translation; the small nuclear RNA U6, central to the spliceosome; and Alu-derived transcripts, including 7SL and BC200 RNAs functional in ubiquitous and neuron-specific signal recognition particles, respectively.^{196,197} An expanding pool of research on RNA Pol III has produced conflicting results on its role in double-strand DNA repair^{198–200} and novel implications in the control of the RNA Pol II transcriptome,²⁰¹ further expanding its role in biological processes.^{201,202} RNA Pol III has unique subunits encoded by *POLR3** genes and shares some subunits with RNA Pol I and RNA Pol II, encoded by *POLR1** and *POLR2** genes, respectively. Complete loss of RNA Pol III-specific subunits is incompatible with life, underscoring that RNA Pol III is a foundational element of cellular function. Hypomorphic variants, which reduce but do not eliminate RNA Pol III function, are the underlying cause of the majority of this group of rare disease entities, often leading to significant morbidity and early mortality.

The most common POLR3-RD is POLR3-related hypomyelinating leukodystrophy (HLD; Phenotype MIM (PMIM): 607694, 614381, 616494, and 619310), also known as 4H leukodystrophy for its cardinal features of hypomyelination, hypodontia, and hypogonadotropic hypogonadism.^{15,30,31,160} Other clinical presentations with predominant neurological involvement associated with pathogenic variants in genes encoding RNA Pol III subunits include hereditary spastic paraparesis and spastic ataxia (HSP/SA)⁷²; mild and severe striatal variant forms (SVFs)^{25,88}; isolated cerebellar atrophy (ICA)¹⁴²; and ataxia, spasticity, demyelinating neuropathy with/without epilepsy (ASDN).^{138,163} Other phenotypes such as intellectual disability or global developmental delay (GDD) with various overlapping features have also been reported.^{135,154,157} Some subtypes of POLR3-RD have significant involvement of non-neurologic tissues or systems, with or without neurologic involvement. These include Wiedemann-Rautenstrauch syndrome (WRS; PMIM: 264090),^{21,22,92} Treacher Collins syndrome (TCS; PMIM: 248390),² isolated hormonal disorder (IHD; e.g., idiopathic hypogonadotropic hypogonadism),^{74,75,156} augmented susceptibility to *Varicella zoster* infection (VZV),^{83,172} endosteal hyperostosis with oligodontia (EHO; PMIM: 619234),^{170,185} and primary ovarian insufficiency (POI).¹⁷⁶ Collectively, reports of these clinical entities describe the spectrum of phenotypes caused by variants impacting RNA Pol III (refer to [Table S2](#) for complete references).

Understanding POLR3-RD biology necessarily involves elucidating the relationships between genotypes and

phenotypes. This has been challenging due to the large number of variants and combinations thereof and the fact that affected RNA Pol III subunit genes and their associated disease subtypes show complex and sometimes overlapping patterns of relationships ([Table 1](#)). Furthermore, phenotypes associated with subunits shared between RNA polymerases may be linked to effects on both RNA Pol III and the other polymerases. For example, craniofacial malformations seen in TCS are thought to be driven primarily by impaired RNA Pol I function, not by impaired RNA Pol III function. Furthermore, in some instances, different genes are associated with the same phenotype (i.e., multigenic disorders), and in other instances, unrelated phenotypes are associated with pathogenic variants in the same gene (i.e., pleiotropic disorders). When considering how to study and clarify these relationships, there are additional complicating factors to consider, including variable disease severity, variable expressivity of disease features, and overlapping phenotypes, i.e., the presence of features characteristic of more than one disorder (e.g., HLD and TCS).⁴ Although genotype-phenotype correlations are key to understanding any genetic disease, only limited comparisons between specific phenotypes have been published,^{15,33} leaving a description of genotype-phenotype relationships among all currently known disease presentations a key gap in POLR3-RD research.

To address this, we systematically searched the literature for information on POLR3-RD genotypes and phenotypes (see [Figures 1](#) and [S1](#) for search details). Literature was obtained from Medline & Embase, Embase Classic (Ovid), and Web of Science (Clarivate). Our search period included all database history until October 31, 2024. The Medline & Embase records were deduplicated automatically using Ovid and EndNote. A manual filtering process was first completed based on titles and abstracts, along with an additional record review for those with uncertain relevance. Records were automatically reviewed for the presence of genotype/phenotype information if they discussed human research and referred to a POLR3-RD diagnosis, RNA Pol III subunit, or *POLR* gene/genotype. Records were automatically excluded if they were associated exclusively with pathogenic variants in genes encoding non-RNA Pol III subunits (e.g., *POLR1A*). Literature was divided and reviewed by five authors (M.A.M.-R., S. G., Q.S., S.P., and A.D.) to ascertain the clinical information for patients reported in the literature, including supplementary data. The final database included patients from 195 published records that reported genetic associations between RNA Pol III subunits and rare developmental or neurological pathologies.

We next collated these published records with records from our international site-specific databases to create a list reflecting all currently known patients. Moreover, an international cross-sectional study was performed from 2019 to 2024, including a retrospective review of patients previously published by our lab and those of

Table 1. References to publications by POLR3-RD gene

Gene	OMIM #	Reference	Associated disorder categories
<i>POLR1C</i>	610060, 616494, 248390	Ching-López et al. ¹ ; Dauwerse et al. ² ; Di Bella et al. ³ ; Gauquelin et al. ⁴ ; Geschwind et al. ⁵ ; Ghesh et al. ⁶ ; Han et al. ⁷ ; Kashiki et al. ⁸ ; Kraoua et al. ⁹ ; Liu et al. ¹⁰ ; Mirchi et al. ¹¹ ; Naseer et al. ¹² ; Pelletier et al. ¹³ ; Schlüter et al. ¹⁴ ; Thiffault et al. ¹⁵ ; Vanderver et al. ¹⁶ ; Yadav et al. ¹⁷ ; Yan et al. ¹⁸	hypomyelinating leukodystrophy; Treacher Collins syndrome
<i>POLR3A</i>	614258, 607694, 264090	Ahmed et al. ¹⁹ ; Al Yazidi et al. ²⁰ ; Arboleda et al. ²¹ ; Arboleda et al. ²² ; Arboleda et al. ²³ ; Arslan et al. ²⁴ ; Azmanov et al. ²⁵ ; Baviera-Muñoz et al. ²⁶ ; Bayram et al. ²⁷ ; Bekiesinska-Figatowska et al. ²⁸ ; Benkirane et al. ²⁹ ; Bernard et al. ³⁰ ; Bernard et al. ³¹ ; Buyukyilmaz et al. ³² ; Báez-Becerra et al. ³³ ; Campopiano et al. ³⁴ ; Casamassa et al. ³⁵ ; Chen et al. ³⁶ ; Chorin et al. ³⁷ ; Cohen et al. ³⁸ ; Córdoba et al. ³⁹ ; D'Amore et al. ⁴⁰ ; Daoud et al. ⁴¹ ; Di Bella et al. ³ ; Di Donato et al. ⁴² ; Dulski et al. ⁴³ ; Fang et al. ⁴⁴ ; Fellner et al. ⁴⁵ ; Fogel et al. ⁴⁶ ; French et al. ⁴⁷ ; Fu et al. ⁴⁸ ; Furukawa et al. ⁴⁹ ; Harting et al. ⁵⁰ ; Hengel et al. ⁵¹ ; Hiraide et al. ⁵² ; Hiraide et al. ⁵³ ; Infante et al. ⁵⁴ ; Jay et al. ⁵⁵ ; Ji et al. ⁵⁶ ; Khalifa et al. ⁵⁷ ; Khan et al. ⁵⁸ ; Kovalskaia et al. ⁵⁹ ; Kunii et al. ⁶⁰ ; Kyle et al. ⁶¹ ; La Piana et al. ⁶² ; Ledesma et al. ⁶³ ; Lessel et al. ⁶⁴ ; Lessel et al. ⁶⁵ ; Liu et al. ¹⁰ ; Lynch et al. ⁶⁶ ; Macaron et al. ⁶⁷ ; Majethia et al. ⁶⁸ ; Maltese et al. ⁶⁹ ; McKenna et al. ⁷⁰ ; Midori et al. ⁷¹ ; Minnerop et al. ⁷² ; Mirchi et al. ¹¹ ; Monteiro et al. ⁷³ ; Montenegro et al. ⁷⁴ ; Montenegro et al. ⁷⁵ ; Moon et al. ⁷⁶ ; Morales et al. ⁷⁷ ; Morales-Rosado et al. ⁷⁸ ; Mrabet et al. ⁷⁹ ; Musumeci et al. ⁸⁰ ; Neocleous et al. ⁸¹ ; Nikkhah et al. ⁸² ; Ogunjimi et al. ⁸³ ; Paolacci et al. ⁸⁴ ; Paolacci et al. ⁸⁵ ; Patel et al. ⁸⁶ ; Pelletier et al. ¹³ ; Peng et al. ⁸⁷ ; Perrier et al. ⁸⁸ ; Perrier et al. ⁸⁹ ; Potic et al. ⁹⁰ ; Potic et al. ⁹¹ ; Rautenstrauch et al. ⁹² ; Ruan et al. ⁹³ ; Ruggiero et al. ⁹⁴ ; Rydning et al. ⁹⁵ ; Saitsu et al. ⁹⁶ ; Schlüter et al. ¹⁴ ; Schobers et al. ⁹⁷ ; Schüle et al. ⁹⁸ ; Shima et al. ⁹⁹ ; Shimojima et al. ¹⁰⁰ ; Sigatullina et al. ¹⁰¹ ; Sun et al. ¹⁰² ; Sytsma et al. ¹⁰³ ; Tailland et al. ¹⁰⁴ ; Tamura et al. ¹⁰⁵ ; Temel et al. ¹⁰⁶ ; Terao et al. ¹⁰⁷ ; Tewari et al. ¹⁰⁸ ; Timmons et al. ¹⁰⁹ ; Travaglini et al. ¹¹⁰ ; Uygun et al. ¹¹¹ ; Venkatraman et al. ¹¹² ; Vázquez-López et al. ¹¹³ ; Wambach et al. ¹¹⁴ ; Wang et al. ¹¹⁵ ; Wolf et al. ¹¹⁶ ; Wolf et al. ¹¹⁷ ; Wolf et al. ¹¹⁸ ; Wu et al. ¹¹⁹ ; Yan et al. ¹⁸ ; Yang et al. ¹²⁰ ; Yang et al. ¹²¹ ; Yau et al. ¹²² ; Yoon Han et al. ¹²³ ; Yu et al. ¹²⁴ ; Zanette et al. ¹²⁵ ; Zea Vera et al. ¹²⁶ ; Zhang et al. ¹²⁷ ; de Assis Pereira Matos et al. ¹²⁸	hypomyelinating leukodystrophy; isolated hormonal disorder, mild and severe striatal forms; hereditary spastic paraparesis/hereditary spastic ataxia; Wiedemann-Rautenstrauch syndrome; VZV infection susceptibility
<i>POLR3B</i>	614366, 614381, 619742	Al Yazidi et al. ²⁰ ; Ando et al. ¹²⁹ ; Bai et al. ¹³⁰ ; Battini et al. ¹³¹ ; Borella et al. ¹³² ; Cayami et al. ¹³³ ; Colona et al. ¹³⁴ ; Daoud et al. ⁴¹ ; Darvish et al. ¹³⁵ ; De Dominicis et al. ¹³⁶ ; DeGasperi et al. ¹³⁷ ; Djordjevic et al. ¹³⁸ ; Fogel et al. ⁴⁶ ; Fukuda et al. ¹³⁹ ; Gach et al. ¹⁴⁰ ; Geroldi et al. ¹⁴¹ ; Ghommid et al. ¹⁴² ; Gutierrez et al. ¹⁴³ ; Hamdan et al. ¹⁴⁴ ; Haneda et al. ¹⁴⁵ ; Jurkiewicz et al. ¹⁴⁶ ; Krygier et al. ¹⁴⁷ ; Kulhánek et al. ¹⁴⁸ ; La Piana et al. ⁶² ; Lin et al. ¹⁴⁹ ; Mahdiah et al. ¹⁵⁰ ; Mattijssen et al. ¹⁵¹ ; Milovanova et al. ¹⁵² ; Mirchi et al. ¹¹ ; Montenegro et al. ⁷⁴ ; Montenegro et al. ⁷⁵ ; Muirhead et al. ¹⁵³ ; Najmabadi et al. ¹⁵⁴ ; Ozgen et al. ¹⁵⁵ ; Pelletier et al. ¹³ ; Perrier et al. ⁸⁸ ; Richards et al. ¹⁵⁶ ; Saghi et al. ¹⁵⁷ ; Saitsu et al. ⁹⁶ ; Schlüter et al. ¹⁴ ; Symonds et al. ¹⁵⁸ ; Synofzik et al. ¹⁵⁹ ; Tétreault et al. ¹⁶⁰ ; Vanderver et al. ¹⁶ ; Verberne et al. ¹⁶¹ ; Wolf et al. ¹¹⁶ ; Wolf et al. ¹¹⁷ ; Wolf et al. ¹¹⁸ ; Wu et al. ¹⁶² ; Xue et al. ¹⁶³ ; Yang et al. ¹⁶⁴ ; Yang et al. ¹⁶⁵ ; Zhang et al. ¹⁶⁶	hypomyelinating leukodystrophy; isolated cerebellar atrophy; cerebellar hypoplasia + endosteal sclerosis/hyperostosis; isolated hormonal disorder; ataxia, spasticity, demyelinating neuropathy with/without epilepsy
<i>POLR3D</i>	187280	Macintosh et al., 2023 ¹⁶⁷	hypomyelinating leukodystrophy
<i>POLR3K</i>	606007, 619310	Dorboz et al. ¹⁶⁸ ; Perrier et al. ¹⁶⁹	hypomyelinating leukodystrophy

References to literature sources for individual disorders are categorized by affected gene with appropriate Online Mendelian Inheritance in Man (OMIM) accessions.




Figure 1. Assembly of patient data by collation of affected individuals from the literature with internal database entries

The literature was searched using Medline, Embase, and Web of Science for literature pertaining to *POLR3** genes and disease until October 31, 2024. The search details can be reviewed in [Figure S1](#). Source data from the primary search yielded 1,422 records, from which 195 relevant records were filtered. Internally, we started with 333 patient files. These were collated together and reviewed for duplicates through a process of matching patients and previous publication records. The process was conservative, meaning that all patient entries are unique and mapped correctly to prior publications, but several patients that were potential duplicates have been excluded as a result of having the same variants and associated clinical data (e.g., birth year, sex, and/or case description).

clinical phenotype, year of birth, and referring physician or publication authorship.

In total, 664 affected individuals were included in the *POLR3*-RD database. All previously reported patients


collaborators. Patients were included if they had pathogenic variants, likely pathogenic variants, and/or variants of uncertain significance (VUS) in genes encoding RNA Pol III subunits and clinical disease consistent with a *POLR3*-RD. This research was approved by the Montreal Children's Hospital and McGill University Health Centre Research Ethics Boards (11-105-PED and 2019-4972). Informed consent was obtained from patients and/or legal guardians. Genetic variants from patient cohorts in our international group were identified by Sanger sequencing of specific genes, gene panels, or exome/genome sequencing using genomic DNA extracted from blood samples using standard protocols, with familial segregation analysis completed to validate variants when DNA was available, as previously described.⁸⁸

In sum, we combined patient data from numerous international experts, including five major university hospitals (McGill University Health Centre [Canada], Children's Hospital of Philadelphia [United States], Amsterdam UMC [the Netherlands], University Hospital Düsseldorf [Germany], and Bambino Gesù Children's Hospital IRCCS [Italy]). Data collection included patient research identifiers, information on prior publication(s), genotype, and *POLR3*-RD diagnosis subtype. The data were collated with those of published cases, and duplicate entries were identified and removed using a conservative process (see [Figure S1](#) for further detail on deduplication; [Table S2](#)). Deduplication of cases was performed across multiple variables, including variants, clinical information such as age of onset, familial history,


were included in the database, but not all were included in the described analysis. We excluded 113 published individuals with 64 unique variants from further analysis (analysis cohort: 551/664 cases, 83.0%) based on the following criteria: known non-RNA Pol III disorder ($n = 51$, e.g., patients with TCS and therefore a disorder mainly driven by RNA Pol I dysfunction and not RNA Pol III), uncertain RNA Pol III impact or atypical gene involvement ($n = 23$), incomplete genetic diagnosis ($n = 16$, e.g., ≥ 1 variant not defined), known alternate variant(s) that may be causal ($n = 12$), or limited clinical information ($n = 11$). For previously reported disease, *POLR3** variant allele frequency was not an exclusion criterion. For new cases, allele frequencies $>0.01\%$ were excluded as part of our variant-filtering process. Notably, the analysis cohort includes 73 novel affected individuals (73/551, 13.2%), including 36 novel *POLR3A* (36/325, 11.1% of *POLR3A*), 33 novel *POLR3B* (33/179, 18.4% of *POLR3B*), and 3 novel *POLR1C* (3/39, 7.7% of *POLR1C*) patients. Further breakdown of the prior publication statistics for affected individuals is given in [Figures 2A](#) and [2B](#) and [Table 2](#).

Genotypes and associated bioinformatics data included in the database were developed after all variants were curated using MobiDetails,²⁰³ and nomenclature was normalized using VariantValidator²⁰⁴ ([Table S3](#)). Identifiers for variants used in the database include HUGO Gene Nomenclature Committee (HGNC) and Human Genome Variation Society (HGVS) nomenclature. We used National Center for Biotechnology Information (NCBI) accessions (chromosome, transcript, and protein)


Patients (N, Percent of Total)



Variants (N, Percent of Total)



Diagnosis Categories (N, Percent of Total)



and included the corresponding Ensembl MANE (matched annotation from NCBI and EBI) transcript. Where discrepancies arose between validated nomenclature and published variants, the corrected variant and original variants were both included, but the corrected variant was used for analysis. Chromosome, coding sequence (CDS), and protein positions were obtained us-

Figure 2. POLR3-RD database breakdown and summary of affected individuals

Patients with POLR3-RD in the analysis cohort are broken down by their causal genes and their status in the literature or as assessed by our team (for previously unpublished patients). Numeric values represent frequencies (counts) and percentages of the total.

(A) Total patients with POLR3-RD, including published and previously unpublished patients broken down by their causal genes.

(B) Previously published affected individuals broken down by their causal genes.

(C) Total variants in the literature regardless of publication status, broken down by their causal genes.

(D) Novel variants that have not yet been published, broken down by genes affected.

(E) POLR3-RD affected individuals grouped by diagnosis category.

ing validated variants. The Ensembl Variant Effect Predictor²⁰⁵ was used to generate and/or fetch bioinformatic data including codon, exon/intron numbers, location annotation, nonsense-mediated decay (NMD) escape predictions, and UTR annotation. Pathogenicity of variants was established through manual variant curation in accordance with the American College of Medical Genetics (ACMG), Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP) variant interpretation guidelines. GeneBe was used for manual curation,²⁰⁶ followed by validation with Franklin (Genoox, Palo Alto, California). Automated curation by both tools was supplemented by manual curation for terms specific to patient phenotype (PP4), familial segregation (PP1 and BS4), *de novo* (PS2 and PM6), *in trans* variants (PM3 and BP2), and functional data (PS2 and PM6). Specific aspects of variant pathogenicity were assessed by *in silico* tools (SIFT,²⁰⁷ PolyPhen2,²⁰⁸ AlphaMissense,²⁰⁹ EVE,²¹⁰ dbSNV,²¹¹ and SpliceAI²¹²) for amino acid conservation, mutation tolerance, structural consequence, functional impact, and splicing effects. Codon sequences before and after variants were ascertained from Ensembl using the primary transcript as reference, and matching codon frequencies were matched to frequency values from the Kasuza Codon Usage Database.²¹³

Table 2. Observations of published and novel/unpublished patients by affected gene

Gene	Patients (n)	Published	Unpublished	Novel (%)
<i>POLR3A</i>	325	289	36	11.1
<i>POLR3B</i>	179	146	33	18.4
<i>POLR1C</i>	39	36	3	7.7
<i>POLR3D</i>	1	1	0	–
<i>POLR3K</i>	3	3	0	–
Multiple*	4	3	1	25.0
Sum	551	478	73	13.2

Asterisk (*) denotes patients with >1 RNA Pol III subunit involvement. This group includes 1 novel patient harboring *POLR3A* and *POLR3B* variants (patient ID #598; see Table S2) and 3 patients with *POLR3A* and *POLR3B* variants previously published and known to our group (patient IDs #380, #381, and #403; see Table S2).¹³

Next, we sought to describe the cohort's variants at the population level. The number of novel/unpublished pathogenic variants in the database is broken down by RNA Pol III subunit gene in Table 3 and Figures 2C and 2D. In the analysis cohort, 551 patients harbored 394 unique variants, of which 31 are previously unpublished (31/394, 7.9%; Table S4). These variants were found as part of 388 unique genotypes (i.e., combinations of variants) in the analysis cohort. Among these unique genotypes, 95 (95/388, 24.5%) were reported in more than one patient, and 27 (27/388, 7.0%) were reported in more than two patients (frequency: 2–9 patients/genotype; Table S4). We observed no discrepancies in diagnoses among patients with the same genotype. 18 patients harbored more than one variant on any individual RNA Pol III subunit gene copy, i.e., had multiple variants in *cis* ("complex/multiallelic variants," 18/551, 3.3%; see Table S2). Among the three more commonly mutated genes (*POLR3A*, *POLR3B*, and *POLR1C*), variants associated with individual disease outcomes did not show a high degree of spatial bias/clustering at the transcript or protein level (Figures 3A–3J). Taken together, most *POLR3*-RDs are recessive, and affected patients have bi-allelic variants in a single RNA Pol III subunit gene, excepting rare cases (e.g., *de novo* *POLR3B* variants causing ASDN). While 25% of individual genotypes have been observed more than once, they result in the same diagnosis (e.g., *POLR3A*: c.1909+18G>A (p.Y637Cfs*14); *POLR3A*: c.1909+18G>A in 9 patients with HLD).

The database contains affected individuals with diagnoses categorized into 12 groups, 7 of which are included in the analysis cohort (HLD, HSP/SA, SVF, WRS, ASDN, ICA, and IHD; Figure 2E). The most frequent diagnosis was HLD, accounting for 321 cases (321/551, 58.3%). Patients are often classified in the literature as being either "typical" or "mild/adult-onset" when features are less severe or when patients are diagnosed incidentally/in adulthood. This suggests a potential underdiagnosed cohort with less severe clinical presentations that may be seen in adult clinics with minimal symptoms or that may not have been seeking medical attention. Genetic screening would increase diagnostic success in this cohort. The typical form is more common, accounting for 312 cases (312/321, 97.2%). However, there was a substantial number of cases where the age of onset was not explicitly discussed in the literature, and the number of mild affected individuals may be underestimated. For example, 3 of 5 known patients with homozygous c.1568T>A (p.V523E) *POLR3B* variants were diagnosed incidentally, suggesting a milder clinical course. Among the HLD cases, there were more patients with *POLR3B* ($n = 143$) than *POLR3A* ($n = 131$) bi-allelic pathogenic variants, even though *POLR3A* has a higher number of unique HLD-associated variants (*POLR3A* 121 vs. *POLR3B* 97). The difference in the number of known variants is not entirely explained by a relative difference in gene size (*POLR3A* chr10:77975149–78029515, 54.4 kb, vs. *POLR3B* chr12:106357748–106510198, 152.5 kb, [GRCh38.p14])

Table 3. Observations of published and novel/unpublished variants by affected gene

Gene	Variants (n)	Published	Unpublished	Novel (%)
<i>POLR3A</i>	218	201	17	7.8
<i>POLR3B</i>	128	116	12	9.4
<i>POLR1C</i>	43	41	2	4.7
<i>POLR3D</i>	2	2	0	–
<i>POLR3K</i>	3	3	0	–
All	394	363	31	7.9

Variants in the database are organized by gene and publication status.




Figure 3. Structural relationships of missense variants associated with specific diagnostic categories at the coding sequence and protein levels

(A–C) Lollipop charts of the most frequently mutated genes, *POLR3A*, *POLR3B*, and *POLR1C*, demonstrating that missense variants typically occur throughout these genes and do not show spatial bias at the level of messenger RNA.

(D–J) Two-dimensional dendrogram representation of the apo protein structure (PDB: 7A6H) reveals that residue positions affected by missense variants causing non-HLD outcomes are sometimes associated with spatial bias/clusters (e.g., ASDN) but often occur in clusters with promiscuous variants.

(legend continued on next page)

but may be explained by the difference in transcript size given that most patients are diagnosed with exome sequencing (*POLR3A* 6,610 bp vs. *POLR3B* 4,183 bp). Among HLD variants, *POLR3A* exhibits greater diversity in variant types, while *POLR3B* is linked to a higher proportion of non-missense variants (Figures 4A and 4B). This is due to the high frequency of *POLR3B* c.1568T>A mutations among patients with *POLR3B* variants (96/193, 49.7%). Additionally, this release includes three novel cases of *POLR1C*-HLD, as well as the only known patient with disease-causing variants in *POLR3D* (Table S5),¹⁶⁷ and a recently published case involving a large deletion in *POLR3K*.¹⁶⁹ Together, HLD variants remain the largest population and most diverse group of variant types among POLR3-RDs (Figures 4A–4E).

HSP/SA is the second most frequent disorder category among patients with RNA Pol III subunit gene variants (Figure 5A). HSP/SA is associated with 57 defined *POLR3A* variants but is primarily defined by a splice-modifying variant that is found in all 93 cases (c.1909+22G>A, p.Y637Cfs*14). The *POLR3A* c.1909+22G>A variant is not exclusive to HSP/SA but shows a strong association. It is also found in 8 patients with Wiedemann Rautenstrauch syndrome (WRS) that have multiallelic genotypes where the c.1909+22G>A variant is always found in *cis* with an additional *POLR3A* variant and another pathogenic variant in *trans*. Notably, none of the patients with HSP/SA with this splicing variant have a second variant in *cis*, further outlining the strong genotype-phenotype correlation. The only known patient with two *POLR3A* c.1909+22G>A variants is categorized as having a mild SVF phenotype due to a concomitant *POLR3A* c.1771–7C>G (p.G548_Y637del/p.P591Mfs*9) (patient ID #66; see Table S2).⁷² Indeed, the homozygous *POLR3A*

c.1909+22G>A genotype is expected to cause no/ extremely mild disease; 10 cases of homozygosity have been reported in gnomAD, suggesting that individuals harboring this genotype may be asymptomatic or perhaps incidentally diagnosed with mild findings late in life.²¹⁴ The similar and nearby *POLR3A* c.1909+18G>A variant is not associated with HSP/SA; however, it has been reported in 9 cases of HLD in homozygous genotypes and 2 cases of WRS in compound-heterozygous genotypes. This evidence thus suggests that the *POLR3A* c.1909+22G>A variant itself is mild, producing an HSP/SA outcome in combination with another variant in *trans*, while having an additional variant in *cis* favors WRS, a more severe outcome.

The SVFs of POLR3-RDs account for 65 cases and are associated with 41 unique variants. Like HSP/SA, SVF cases are also defined by the involvement of a canonical locus: two adjacent variants located in a polypyrimidine tract in intron 13 of *POLR3A* (Figure 5B). Each affected individual has at least one copy of *POLR3A* c.1771–6C>G (p.G548_Y637del/p.P591Mfs*9) (25/65, 38.5%) or *POLR3A* c.1771–7C>G/A (39/65, 60.0%) or both in *trans* (1/65, 1.5%). Both of these variants cause similar leaky splicing defects and are associated with specific disease manifestations and MRI features characterized by a neurodegenerative process affecting the striatum.^{25,88} We hypothesized that disease severity is related to the combination of alleles, including the variant inherited in *trans* with the canonical splice variant (here, c.1771–6C>G or c.1771–7C>G). The hypothesis postulates that individuals with two canonical variants have the mildest course and cases with a canonical variant and an amorphic variant have the most severe course, while the severity of cases having other types of variants in *trans* (e.g.,

(A) *POLR3A* missense variants occur throughout the coding sequence and are associated with multiple diagnoses. *POLR3A* missense variants causing specific disease outcomes have low spatial bias. The most frequently observed *POLR3A* missense variants are c.2554A>G (p.M852V), associated with multiple outcomes, and c.2015G>A (p.G672E), associated uniquely with HLD outcomes.

(B) *POLR3B* missense variants occur throughout the coding sequence and are associated with multiple diagnoses. *POLR3B* missense variants causing specific disease outcomes have low spatial bias. The most frequently observed *POLR3B* missense variants are c.1568T>A and c.1244T>C (p.M415T), both associated with multiple outcomes.

(C) *POLR1C* missense variants occur throughout the coding sequence and are associated primarily with HLD outcomes. The most frequently observed *POLR1C* missense variants are c.836G>A (p.R279Q) and c.193A>G (p.M65V). The former is associated with a position affected in multiple disease outcomes.

(D) A two-dimensional circular dendrogram representation of the apo RNA Pol III structure developed by Girbig et al. (PDB: 7A6H) was assembled using alpha carbon positions of individual residues, and clustering was done using Ward's minimum variance method. As pictured, variants closer to each other along the perimeter of the dendrogram are more closely associated in the three-dimensional RNA Pol III structure. Cluster height is represented as ($r = \log_2(\text{cluster height})$), and increasingly peripheral nodes merge clusters with lower spatial variance (i.e., residues that are closer together merge at more peripheral nodes). Residues of specific RNA Pol III subunits are colored according to the legend pictured on the right of the diagram.

(E) RNA Pol III residues affected by missense variants implicated in HLD occur broadly throughout the polymerase and display low spatial bias.

(F) RNA Pol III residues affected by missense variants implicated in WRS are rare. Many occur in clusters populated by residues that are also implicated in association with multiple outcomes.

(G) RNA Pol III residues affected by missense variants implicated in HSP/SA often occur in clusters populated by residues that are also implicated in association with multiple outcomes.

(H) Missense variants causing ASDN occur in *POLR3B*. These variants typically fall into one of three unique spatial clusters of *POLR3B* residues that are thought to be involved in nucleic acid interactions.

(I) Missense variants associated with SVF outcomes are typically found in clusters populated by residues that are also implicated in association with multiple outcomes.

(J) Residue positions affected by missense variants causing multiple outcomes (i.e., promiscuous variants) are pictured. Underlying data for D–J can be found in Table S6.




Figure 4. Hypomyelinating leukodystrophy variant frequency by gene (*n*) and type (proportion)

Frequency (no. of unique variants) and relative proportion (percentage) of types of variants among patients with POLR3-related hypomyelinating leukodystrophy. Variants can have multiple type classifications; the relative proportion represents the frequency of variants of a particular gene and type divided by the total number of instances of classification for that gene.

(A) HLD is associated with 121 unique *POLR3A* variants in the database, of which the majority are missense variants ($n = 88$). The next most frequent variant types are splice ($n = 16$) and stop-gain ($n = 12$) variants.

(B) *POLR3B* is associated with 97 unique variants. The most frequent are missense ($n = 57$) followed by splice ($n = 19$) and stop-gain ($n = 12$) variants.

(C) *POLR1C* variants ($n = 43$) are mainly missense ($n = 35$). The next most frequent are splicing ($n = 4$) and frameshift ($n = 4$) variants.

(D) *POLR3D* variants ($n = 2$) include an intronic variant in a polypyrimidine tract and another that is a missense variant.

(E) *POLR3K* is known for two missense variants and a large deletion involving the entirety of exon 3 (the final exon), predicted to cause frameshift/stop gain. The underlying basis of the low diversity among *POLR3D* and *POLR3K* variants is the low frequency of total observations in the population and not a relationship between these subunits and a particular type of variant.

missense or splice) is related to their severity. We tested this hypothesis using a total of 39 of 42 genotypes—excluding 3 with conflicting reports of severity.^{10,44,50,115}

SVF cases ($n = 16$) with homozygous or compound heterozygous canonical variants (i.e., homozygous c.1771–6C>G or c.1771–7C>G; compound heterozygous c.1771–6C>G; c.1771–7C>G) all have mild disease. Of 21 SVF cases with missense variants found in *trans* with the canonical variant, 20 have mild disease (95.2%). Additionally, a single known SVF individual with a canonical variant and an in-frame deletion in *trans* exhibits mild disease.¹²³ In SVF cases where variants found in *trans* cause premature termination of translation (i.e., predicted loss of function), all 13 affected

individuals are classified as having severely affected individuals. Of all severe cases ($n = 18$), 5 are not obviously associated with premature termination of translation. In 2 individuals, there are non-canonical splice variants in *trans* (patient IDs #251 and #252; see Table S2),⁵⁰ 2 are previously unpublished patients where the canonical allele is found in the context of a multiallelic genotype (>2 alleles, patient IDs #421 and #422; see Table S2), and the final affected individual is known to have a missense variant in *trans* that does not cause premature termination of translation (patient ID #253; see Table S2).⁵⁰ This *POLR3A* c.2713G>A (p.D905N) variant produces a deleterious substitution in a region of the RNA Pol III foot domain. A homologous domain in




Figure 5. Variant frequency by gene (*n*) and type (proportion) among other presentations of POLR3-related disorders
Frequency (no. of unique variants) and relative proportion (percentage) of types of variants among patients with POLR3-related disorders. Variants can have multiple type classifications; the relative proportion represents the frequency of variants of a particular gene and type divided by the total number of instances of classification for that gene.
(A) HSP/SA is associated with 57 unique *POLR3A* variants. Observations of *POLR3A* missense variants (*n* = 22) are proportionally lower among patients with HSP/SA than among patients with HLD, while stop-gain variants (*n* = 15) are more frequent overall. The next most frequent variants among *POLR3A* are frameshift (*n* = 11) or splicing (*n* = 11) variants.
(B) SVF is associated exclusively with *POLR3A* variants (*n* = 40), and all cases have at least one allele that is either *POLR3A* c.1771–6C>G or *POLR3A* c.1771–7C>G. Examination of the total variant population reveals that most non-canonical variants are missense (*n* = 19), splicing (*n* = 7), stop gain (*n* = 6), or frameshift (*n* = 5). These exemplify typical variants found *in trans* in patients with SVF.
(C) Unique *POLR3A* variants (*n* = 32) associated with WRS are typically missense (*n* = 10), splice (*n* = 10), or stop gains (*n* = 6).
(D) There are 3 unique *POLR3B* missense variants associated with WRS.
(E) There are 22 unique *POLR3B* missense variants associated with cases of ASDN. These are all inherited *de novo*, making them unique as compared to all other variants causing POLR3-RD.

RNA Pol II has a role in regulating proximal promoter pausing and chromatin modification.^{50,215,216} While these activities have not been shown for the homologous RNA Pol III domain, it has co-evolved with its RNA Pol II equivalent,²¹⁵ suggesting the possibility of an important functional role that produces effects similar to an amorphic variant when lost.

Of the 8 SVF affected individuals with a non-canonical splice variant *in trans* (non-c.1771–6C>G, non-c.1771–7C>G), 4 have mild disease (4/8, 50.0%). Bioinformatics predictions for splicing variants included

here do not predict the severity of the outcome, while the predicted sequence ontology impact was not well correlated with clinical outcomes. Based on our understanding of the other cases, we hypothesize that severely affected individuals with non-canonical splice variants *in trans* should be those causing more substantial reductions in functional protein levels. To thoroughly address and validate this hypothesis, functional studies will be essential to draw definitive conclusions and provide a deeper understanding of the underlying mechanisms.

In the initial dataset, the TCS category included 45 cases implicating *POLR1D*, 5 cases implicating *POLR1C*, and 1 case with an 889 kb deletion involving *POLR3C*.¹⁷³ Previous work has shown that pathogenic variants causing POLR3-RDs, such as HLD, impact RNA Pol III, whereas those associated with TCS are known to impact RNA Pol I. Indeed, in TCS, pathogenic variants affect the dimerization interface between *POLR1C* and *POLR1D*, leading to disrupted RNA Pol I nucleolar localization and abnormal ribosomal biogenesis.^{2,15,177,183,217–219} We observed that all patients harboring *POLR1C* variants with TCS have an allele with a small in-frame deletion or missense variant in the dimerization domain and a stop-gain variant on the other allele, except one patient who has a splicing variant predicted to cause loss of exon 8 (and loss of the dimerization domain) in *trans* with a missense variant (patient ID #40). By contrast, patients with HLD have missense-only genotypes or small deletions in *trans* with missense mutations but do not carry stop-gain variants in *trans*. Four patients with HLD and variants causing frameshift and premature termination of translation harbor missense variants outside of the dimerization domain in *trans* (patient IDs #319, #320, #322, and #324). Interestingly, it is possible to have phenotypic overlap between TCS and POLR3-RD. For example, one of the patients harboring a small in-frame deletion and a nonsense *POLR1C* variant is known to have both HLD and TCS features concurrently (patient ID #329; see Table S2).^{4,11}

WRS is a diagnostic category comprising patients with a connective tissue disorder known to be caused by variants in *POLR3A* and *POLR3B* (Figures 5C and 5D). There are 35 patients with WRS caused by variants in *POLR3A*, and 3 with WRS caused by *POLR3B*. Of the 3 WRS-associated *POLR3B* variants, two are unique to WRS and are found in a compound heterozygous state (*POLR3B* c.2191G>C (p.E731Q); c.3046G>A (p.V1016M)),¹⁶² while one that is homozygous in WRS (*POLR3B* c.1625A>G (p.N542S))¹⁵¹ has also been observed in the heterozygous state in association with ICA (*POLR3B* c.1625A>G; c.707T>C (p.I236T)).

Overall, there are 29 genotypes associated with the WRS diagnosis category, including a variety of variant types. Start or stop sites are affected in 10 genotypes, causing initiator loss or premature termination of translation (10/29, 34.5%, $n = 13$ patients). There are 5 genotypes that have missense variants alone (5/29, 17.2%, $n = 9$ patients), including the only 2 *POLR3B* genotypes, 7 genotypes that have only splice variants (7/29, 24.1%, $n = 8$ patients), and 1 genotype that is homozygous for a synonymous *POLR3A* variant (1/29, 3.4%, $n = 1$ patient). The remaining genotypes, including 3 of the genotypes affected by premature termination of translation, have alleles with mixed downstream consequences. Additionally, 7 total genotypes are multiallelic and include the *POLR3A* c.1909+22G>A, c.3337–11T>C (p.I1113_E1143del) alleles found in *cis* (7/29, 24.1%, $n = 8$ patients with $n = 7$ genotypes; genotype IDs #89, #262, #271, #272, #279, #293, and #354; see Table S4).

We found that, invariably, genotypes causing WRS included at least one allele that could be considered more severe, for example, null-equivalent variants or missense variants with higher predicted functional impact according to bioinformatics tools (e.g., SIFT, PolyPhen2, AlphaMissense, and EVE). Although in many cases, the severity of variants was self-evident (e.g., variants causing premature termination), cases involving only splicing or missense variants are less so. Because splicing variants require experimental evaluation, we analyzed SIFT, PolyPhen2, and AlphaMissense severity of missense variants associated with each of the WRS cases having genotypes with missense alleles only. A non-parametric two-sided Wilcoxon rank-sum test with continuity correction (data are not normally distributed) was performed on the most severe missense allele for each WRS case. There was a statistical difference in SIFT and PolyPhen2 severity scores of these WRS variants vs. all other non-WRS variants in the database (SIFT $W = 6355.5$, $p = 1.23 \times 10^{-9}$; PolyPhen2 $W = 5507.5$, $p = 1.62 \times 10^{-4}$). Evaluation of the same groups' AlphaMissense severity using parametric two-tailed Student's *t* test with Welch's correction (data are normally distributed) revealed a statistically significant difference ($t = 3.022$, degrees of freedom(df) = 9.361, $p = 0.0138$). This result supports the validity of a potential association between exceptionally severe alleles and WRS outcomes in missense-only cases, but bioinformatics tools alone are not sufficient to conclude whether WRS cases are always associated with exceptionally severe variants. Further functional validation is required to support the hypothesis suggested by these *in silico* results. Moreover, it would be necessary to extend the analysis to confirm a similar association among cases with splicing variants only.

Finally, 22 known *de novo* missense variants in *POLR3B* are associated with ASDN ($n = 23$ cases; Figure 5E).^{129,134,136,138,139,141,149,158,163} These variants are unique to this diagnosis and never associated with other POLR3-RDs, highlighting their unique mechanism, which is proposed to involve altered function at DNA-interacting elements in RNA Pol III.^{138,158} There are a handful of even rarer presentations of POLR3-RDs, including IHD cases such as idiopathic hypogonadotropic hypogonadism and severe VZV cases caused by *POLR3A* variants that are dominant and specific to viral susceptibility, ICA, POI, and EHO. Together, these account for 32 cases (32/664, 4.8% of the total database). Among them, cases of IHD, VZV, and ICA account for 25 cases, or 78.1% of this category of rare presentations.

In conclusion, we developed a comprehensive database of all known patients with POLR3-RDs and their associated diagnoses and disease-causing variants. This allowed us to elucidate genotype-phenotype relationships, including notable associations between specific variants and clinical outcomes, such as the link between *POLR3A* c.1771–6C>G and c.1771–7C>G with SVF or *POLR3A* c.1909+22G>A and HSP/SA. Additionally, we explored

the molecular pathogenesis underlying distinct phenotypic presentations, such as WRS. Notably, this study introduces 73 new cases and 31 novel variants to the literature, significantly expanding the current knowledge of genotype-phenotype correlations across the POLR3-RD spectrum. These findings provide immediate value for patient and family counseling while also contributing to a deeper understanding of disease presentation and progression, which is critical for designing future clinical trials and ensuring effective patient stratification.

Acknowledgments

The group would like to acknowledge the generous support of the patients and families contributing to this research. This study was funded by research grants from the Canadian Institutes of Health Research (CIHR; PJT-168887) and the Montreal Children's Hospital Foundation/Leuco Action. M.A.M.-R. would like to acknowledge the Vanier Canada Graduate Scholarship and the McGill University Faculty of Medicine for their generous support. S.P. has been supported by the Fonds de Recherche du Québec - Santé (FRQS) Doctoral Scholarship, the Fondation du Grand défi Pierre Lavoie Doctoral Scholarship, the McGill Faculty of Medicine F.S.B. Miller Fellowship, and the Research Institute of the McGill University Health Centre Desjardins Studentship in Child Health Research. S.G. received support from the CIHR Master's Scholarship and the Research Institute of the McGill University Health Centre Master's Studentship. L.G. has received grants from the Canadian Gene Cure Advanced Therapies for Rare Disease (Can-GARD, 2018) and from R.S. McLaughlin and Teva Canada Innovation funds from the Faculty of Medicine, Université Laval (2018). F.N. and E.B. are members of the European Reference Network for Rare Neurological Diseases, project ID no. 739510. G.B. has received the Clinical Research Scholar Junior 1 Award from the FRQS (2012–2016), the New Investigator Salary Award from the CIHR (2017–2022), the Clinical Research Scholar Senior award from the FRQS (2022–2025), and the Chercheur de Mérite award from the FRQS (2025–2029).

Author contributions

M.A.M.-R. wrote the manuscript, developed the database, analyzed data, and contributed to the literature review. S.P. developed the database and contributed to literature review. S.G. developed the database, variant validation, and curation methods and data and contributed to literature review. A.D. developed the database and contributed to literature review. Q. S. developed variant validation and curation methods and data. M.G. developed RNA Pol III models and contributed to understanding variant severity. A.D.M. developed RNA Pol III models and contributed to understanding variant severity. A.M.P., D.L.R., D.D.A.P., P.O., L.M.K., S.K., K.C., L.G., B.B., M.M., B.L., T.G., M.E.S., R.S., E.B., F.N., D.T., A.V., and N.I.W. contributed patients and expertise and participated in the editing of the manuscript. C.W.M. contributed expertise, supervised student authors, and participated in developing the projects and editing the manuscript. G.B. contributed patients and expertise, supervised student authors, and participated in developing projects and editing the manuscript.

Declaration of interests

M.M. serves on the medical advisory board of the German Heredo Ataxia Society (DHAG) and received honoraria from Biogen, unrelated to this research. G.B. is/was a consultant for Calico (2023–present), Orchard Therapeutics (2023), Passage Bio, Inc. (2020–2022), and Ionis (2019). She is/was a site investigator/sub-I for trials and natural histories of Calico/Abbvie (2024–present), Ionis (2021–present), Shire/Takeda (2020–2021), Passage Bio (2021–2024), Bluebird Bio (2019), Regeneron (2021–present), and Denali (2022–present). She has received an unrestricted educational grant from Takeda (2021–2022). She serves on the Scientific Advisory board of the Pelizaeus-Merzbacher Foundation, the Yaya Foundation Scientific and Clinical Advisory Council, and the Medical and Scientific Advisory Board of the United Leukodystrophy Foundation.

Web resources

AlphaMissense, <https://alphamissense.hegelab.org>
dbSNP, <http://www.ncbi.nlm.nih.gov/snp/>
Ensembl VEP, <https://ensembl.org/info/docs/tools/vep/index.html>
EVE, <https://evemodel.org>
Franklin (Genoox), <https://franklin.genoox.com/clinical-db/home>
GeneBe, <https://genebe.net>
OMIM, <https://www.omim.org>
PDB, <https://www.rcsb.org>
PolyPhen2, <http://genetics.bwh.harvard.edu/pph2/>
SIFT, <https://sift.bii.a-star.edu.sg>
SpliceAI, <https://spliceailookup.broadinstitute.org>

Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.xhgg.2025.100481>.

Received: April 18, 2025

Accepted: July 13, 2025

References

- Ching-López, A., Martinez-Gonzalez, L.J., Arrabal, L., Sáiz, J., Gavilán, Á., Barbas, C., Lorente, J.A., Roldán, S., Sánchez, M.J., and Gutierrez-Ríos, P. (2021). Combined Genome, Transcriptome and Metabolome Analysis in the Diagnosis of Childhood Cerebellar Ataxia. *Int. J. Mol. Sci.* 22, 2990.
- Dauwerse, J.G., Dixon, J., Seland, S., Ruivenkamp, C.A.L., van Haeringen, A., Hoefsloot, L.H., Peters, D.J.M., Boers, A.C.d., Daumer-Haas, C., Maiwald, R., et al. (2011). Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome. *Nat. Genet.* 43, 20–22.
- Di Bella, D., Magri, S., Benzoni, C., Farina, L., Maccagnano, C., Sarto, E., Moscatelli, M., Baratta, S., Ciano, C., Piacentini, S.H.M.J., et al. (2021). Hypomyelinating leukodystrophies in adults: Clinical and genetic features. *Eur. J. Neurol.* 28, 934–944.
- Gauquelin, L., Cayami, F.K., Sztriha, L., Yoon, G., Tran, L. T., Guerrero, K., Hocke, F., van Spaendonk, R.M.L., Fung, E.L., D'Arrigo, S., et al. (2019). Clinical spectrum of

- POLR3-related leukodystrophy caused by biallelic POLR1C pathogenic variants. *Neurol. Genet.* 5, e369.
5. Geschwind, M., Kim, M.O., Wahl, C., Gahl, W., and Toro, C. (2016). A novel POLR1C mutation causing autosomal recessive adult-onset leukodystrophy. In *Neurology Conference: 68th American Academy of Neurology Annual Meeting*, AAN 86.
 6. Ghesh, L., Vincent, M., Delemazure, A.S., Boyer, J., Corre, P., Perez, F., Geneviève, D., Laplanche, J.L., Collet, C., and Isidor, B. (2019). Autosomal recessive Treacher Collins syndrome due to POLR1C mutations: Report of a new family and review of the literature. *Am. J. Med. Genet.* 179, 1390–1394.
 7. Han, J.Y., Kim, S.Y., Cheon, J.E., Choi, M., Lee, J.S., and Chae, J.H. (2020). A Familial Case of Childhood Ataxia with Leukodystrophy Due to Novel POLR1C Mutations. *J. Clin. Neurol.* 16, 338–340.
 8. Kashiki, H., Li, H., Miyamoto, S., Ueno, H., Tsurusaki, Y., Ikeda, C., Kurata, H., Okada, T., Shimazu, T., Imamura, H., et al. (2020). POLR1C variants dysregulate splicing and cause hypomyelinating leukodystrophy. *Neurol. Genet.* 6, e524.
 9. Kraoua, I., Karkar, A., Drissi, C., Benrhouma, H., Klaa, H., Samaan, S., Renaldo, F., Elmaleh, M., Ben Hamouda, M., Abdelhak, S., et al. (2019). Novel POLR1C mutation in RNA polymerase III-related leukodystrophy with severe myoclonus and dystonia. *Mol. Genet. Genomic Med.* 7, e914.
 10. Liu, J., Niu, Y., Qin, J., and Yang, Z. (2024). POLR3-related leukodystrophy caused by biallelic POLR3A and 1C pathogenic variants: a single-center experience. *Front. Neurol.* 15, 1355484.
 11. Mirchi, A., Guay, S.P., Tran, L.T., Wolf, N.I., Vanderver, A., Brais, B., Sylvain, M., Pohl, D., Rossignol, E., Saito, M., et al. (2023). Craniofacial features of POLR3-related leukodystrophy caused by biallelic variants in POLR3A, POLR3B and POLR1C. *J. Med. Genet.* 60, 1026–1034.
 12. Naseer, M.I., Abdulkareem, A.A., Pushparaj, P.N., Saharti, S., and Muthaffar, O.Y. (2022). Next-Generation Sequencing Reveals Novel Homozygous Missense Variant c.934T > C in POLR1C Gene Causing Leukodystrophy and Hypomyelinating Disease. *Front. Pediatr.* 10, 862722.
 13. Pelletier, F., Perrier, S., Cayami, F.K., Mirchi, A., Saikali, S., Tran, L.T., Ulrick, N., Guerrero, K., Rampakakis, E., van Spaendonk, R.M.L., et al. (2021). Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C. *J. Clin. Endocrinol. Metab.* 106, e660–e674.
 14. Schlüter, A., Rodríguez-Palmero, A., Verdura, E., Vélez-Santamaría, V., Ruiz, M., Fourcade, S., Planas-Serra, L., Martínez, J.J., Guilera, C., Girós, M., et al. (2022). Diagnosis of Genetic White Matter Disorders by Singleton Whole-Exome and Genome Sequencing Using Interactome-Driven Prioritization. *Neurology* 98, e912–e923.
 15. Thiffault, I., Wolf, N.I., Forget, D., Guerrero, K., Tran, L.T., Choquet, K., Lavallée-Adam, M., Poitras, C., Brais, B., Yoon, G., et al. (2015). Recessive mutations in POLR1C cause a leukodystrophy by impairing biogenesis of RNA polymerase III. *Nat. Commun.* 6, 7623.
 16. Vanderver, A., Simons, C., Helman, G., Crawford, J., Wolf, N.I., Bernard, G., Pizzino, A., Schmidt, J.L., Takanohashi, A., Miller, D., et al. (2016). Whole exome sequencing in patients with white matter abnormalities. *Ann. Neurol.* 79, 1031–1037.
 17. Yadav, N., Saini, J., and Nagappa, M. (2021). Novel Mutation in the POLR1C Gene Causing Hypomyelinating Leukodystrophy in an Adult. *Neurol. Clin. Pract.* 11, e367–e369.
 18. Yan, H., Ji, H., Kubisiak, T., Wu, Y., Xiao, J., Gu, Q., Yang, Y., Xie, H., Ji, T., Gao, K., et al. (2021). Genetic analysis of 20 patients with hypomyelinating leukodystrophy by trio-based whole-exome sequencing. *J. Hum. Genet.* 66, 761–768.
 19. Ahmed, H.S., Belarbi, O., Daoudi, S., Labauge, P., Dallier Clarisse, C., Perrine, S., Pauline, S., Drunat, S., and Cavé, H. (2022). A new rare homozygous mutation in the POLR3A gene causes ataxo-spasmodic leukodystrophy. *Rom. J. Neurol.* 21, 115–118.
 20. Al Yazidi, G., Tran, L.T., Guerrero, K., Vanderver, A., Schiffmann, R., Wolf, N.I., Chouinard, S., and Bernard, G. (2019). Dystonia in RNA Polymerase III-Related Leukodystrophy. *Mov. Disord. Clin. Pract.* 6, 155–159.
 21. Arboleda, H., Quintero, L., and Yunis, E. (1997). Wiedemann-Rautenstrauch neonatal progeroid syndrome: report of three new patients. *J. Med. Genet.* 34, 433–437.
 22. Arboleda, H., and Arboleda, G. (2005). Follow-up study of Wiedemann-Rautenstrauch syndrome: long-term survival and comparison with Rautenstrauch's patient "G". *Birth Defects Res. A Clin. Mol. Teratol.* 73, 562–568.
 23. Arboleda, G., Morales, L.C., Quintero, L., and Arboleda, H. (2011). Neonatal progeroid syndrome (Wiedemann-Rautenstrauch syndrome): report of three affected sibs. *Am. J. Med. Genet.* 155a, 1712–1715.
 24. Arslan, E.A., Öncel, İ., Ceylan, A.C., Topçu, M., and Topaloglu, H. (2020). Genetic and phenotypic features of patients with childhood ataxias diagnosed by next-generation sequencing gene panel. *Brain Dev.* 42, 6–18.
 25. Azmanov, D.N., Siira, S.J., Chamova, T., Kaprelyan, A., Guergueltcheva, V., Shearwood, A.J., Liu, G., Morar, B., Rackham, O., Bynevelt, M., et al. (2016). Transcriptome-wide effects of a POLR3A gene mutation in patients with an unusual phenotype of striatal involvement. *Hum. Mol. Genet.* 25, 4302–4314.
 26. Baviera-Muñoz, R., Carretero-Villarraig, L., Vázquez-Costa, J. F., Morata-Martínez, C., Campins-Romeu, M., Muelas, N., Sastre-Bataller, I., Martínez-Torres, I., Pérez-García, J., Sivera, R., et al. (2022). Diagnostic Efficacy of Genetic Studies in a Series of Hereditary Cerebellar Ataxias in Eastern Spain. *Neurol Genet* 8, e200038.
 27. Bayram, Y., Karaca, E., Coban Akdemir, Z., Yilmaz, E.O., Tayfun, G.A., Aydin, H., Torun, D., Bozdogan, S.T., Gezdirici, A., Isikay, S., et al. (2016). Molecular etiology of arthrogryposis in multiple families of mostly Turkish origin. *J. Clin. Invest.* 126, 762–778.
 28. Bekiesinska-Figatowska, M., Mierzewska, H., Kuczynska-Zardzewialy, A., Szczepanik, E., and Obersztyn, E. (2010). Hypomyelination, hypogonadotropic hypogonadism, hypodontia - First Polish patient. *Brain Dev.* 32, 574–578.
 29. Benkirane, M., Marelli, C., Guissart, C., Roubertie, A., Ollagnon, E., Choumert, A., Fluchère, F., Magne, F.O., Halleb, Y., Renaud, M., et al. (2021). High rate of hypomorphic variants as the cause of inherited ataxia and related diseases: study of a cohort of 366 families. *Genet. Med.* 23, 2160–2170.
 30. Bernard, G., Thiffault, I., Tetreault, M., Putorti, M.L., Bouchard, I., Sylvain, M., Melançon, S., Laframboise, R.,

- Langevin, P., Bouchard, J.P., et al. (2010). Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31. *Neurogenetics* 11, 457–464.
31. Bernard, G., Chouery, E., Putorti, M.L., Tétreault, M., Takanohashi, A., Carosso, G., Clément, I., Boespflug-Tanguy, O., Rodriguez, D., Delague, V., et al. (2011). Mutations of POLR3A encoding a catalytic subunit of RNA polymerase Pol III cause a recessive hypomyelinating leukodystrophy. *Am. J. Hum. Genet.* 89, 415–423.
32. Buyukyilmaz, G., Erozan Cavdarlı, B., Toksoy Adiguzel, K., Adiguzel, M., Kasapkara, C.S., Gurbuz, F., Boyraz, M., and Gurkas, E. (2023). The First Case of 4H Syndrome with Type 1 Diabetes Mellitus. *J. Clin. Res. Pediatr. Endocrinol.* 17, 103–108.
33. Báez-Becerra, C.T., Valencia-Rincón, E., Velásquez-Méndez, K., Ramírez-Suárez, N.J., Guevara, C., Sandoval-Hernandez, A., Arboleda-Bustos, C.E., Olivos-Cisneros, L., Gutiérrez-Ospina, G., Arboleda, H., and Arboleda, G. (2020). Nucleolar disruption, activation of P53 and premature senescence in POLR3A-mutated Wiedemann-Rautenstrauch syndrome fibroblasts. *Mech. Ageing Dev.* 192, 111360.
34. Campopiano, R., Ferese, R., Zampatti, S., Giardina, E., Biagioni, F., Colonnese, C., Centonze, D., Storto, M., Buttari, F., Fraviga, E., et al. (2020). A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset. *BMC Neurol.* 20, 258.
35. Casamassa, A., Rotundo, G., Ceresoni, C., Turco, E.M., Torrente, I., Candido, O., Nicita, F., Tonduti, D., Bertini, E., Marano, M., et al. (2024). Production of an induced pluripotent stem cell line CSSi018-A (14192) from a patient with hypomyelinating leukodystrophy 7 (HLD7) carrying biallelic variants of POLR3A (c.1802 T > A; c.4072G > A). *Stem Cell Res.* 78, 103468.
36. Chen, J., Zhao, Z., Shen, H., Bing, Q., Li, N., Guo, X., and Hu, J. (2022). Genetic origin of patients having spastic paraplegia with or without other neurologic manifestations. *BMC Neurol.* 22, 180.
37. Chorin, O., Shani, H., Moran, G., Inbar, N.H., Pode-Shakked, B., and Raas-Rothschild, A. (2022). eP099: Wiedemann-Rautenstrauch syndrome- New pathways for an old disease. *Genet. Med.* 24, S65.
38. Cohen, L., Manín, A., Medina, N., Rodríguez-Quiroga, S., González-Morón, D., Rosales, J., Amartino, H., Specola, N., Córdoba, M., Kauffman, M., and Vega, P. (2020). Argentinian clinical genomics in a leukodystrophies and genetic leukoencephalopathies cohort: Diagnostic yield in our first 9 years. *Ann. Hum. Genet.* 84, 11–28.
39. Córdoba, M., Rodríguez-Quiroga, S.A., Vega, P.A., Salinas, V., Perez-Maturo, J., Amartino, H., Vásquez-Dusefante, C., Medina, N., González-Morón, D., and Kauffman, M.A. (2018). Whole exome sequencing in neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach. *PLoS One* 13, e0191228.
40. D'Amore, A., Tessa, A., Casali, C., Dotti, M.T., Filla, A., Silvestri, G., Antenora, A., Astrea, G., Barghigiani, M., Battini, R., et al. (2018). Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study. *Front. Neurol.* 9, 981.
41. Daoud, H., Tétreault, M., Gibson, W., Guerrero, K., Cohen, A., Gburek-Augustat, J., Synofzik, M., Brais, B., Stevens, C.A., Sanchez-Carpintero, R., et al. (2013). Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism. *J. Med. Genet.* 50, 194–197.
42. Di Donato, I., Gallo, A., Ricca, I., Fini, N., Silvestri, G., Gurrieri, F., Cirillo, M., Cerase, A., Natale, G., Matrone, F., et al. (2022). POLR3A variants in hereditary spastic paraparesis and ataxia: clinical, genetic, and neuroradiological findings in a cohort of Italian patients. *Neurol. Sci.* 43, 1071–1077.
43. Dulski, J., Middlebrooks, E.H., and Wszolek, Z.K. (2024). Novel Neuroimaging Pattern in POLR3A-Related Disorder on 7T MRI. *Neurol. Genet.* 10, e200125.
44. Fang, H., Leilei, M., Nan, P., Fei, Y., Jing, P., and Li, Y. (2021). Compound heterozygous mutations in POLR3A gene cause global developmental delay with epilepsy and striatal degeneration. *Chin. J. Neurol.* 54, 1282–1289. [Chinese].
45. Fellner, A., Lossos, A., Kogan, E., Argov, Z., Gonzaga-Jauregui, C., Shuldiner, A.R., Darawshe, M., Bazak, L., Lidzbarsky, G., Shomron, N., et al. (2021). Two intronic cis-acting variants in both alleles of the POLR3A gene cause progressive spastic ataxia with hypodontia. *Clin. Genet.* 99, 713–718.
46. Fogel, B.L., Lee, H., Deignan, J.L., Strom, S.P., Kantarci, S., Wang, X., Quintero-Rivera, F., Vilain, E., Grody, W.W., Perlman, S., et al. (2014). Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia. *JAMA Neurol.* 71, 1237–1246.
47. French, C.E., Dolling, H., Mégy, K., Sanchis-Juan, A., Kumar, A., Delon, I., Wakeling, M., Mallin, L., Agrawal, S., Austin, T., et al. (2022). Refinements and considerations for trio whole-genome sequence analysis when investigating Mendelian diseases presenting in early childhood. *Human Genetics and Genomics Advances* 3, 100113.
48. Fu, F., Li, R., Li, Y., Nie, Z.Q., Lei, T., Wang, D., Yang, X., Han, J., Pan, M., Zhen, L., et al. (2018). Whole exome sequencing as a diagnostic adjunct to clinical testing in fetuses with structural abnormalities. *Ultrasound Obstet. Gynecol.* 51, 493–502.
49. Furukawa, S., Kunii, M., Doi, H., Kondo, N., Ogura, A., Hirabuki, K., Itoh, T., Matsumoto, N., Tanaka, F., Katsuno, M., and Ito, Y. (2021). Case Report: Severe Osteoporosis and Preventive Therapy in RNA Polymerase III-Related Leukodystrophy. *Front. Neurol.* 12, 622355.
50. Harting, I., Al-Saady, M., Krägeloh-Mann, I., Bley, A., Hempel, M., Bierhals, T., Karch, S., Moog, U., Bernard, G., Huntsman, R., et al. (2020). POLR3A variants with striatal involvement and extrapyramidal movement disorder. *Neurogenetics* 21, 121–133.
51. Hengel, H., Buchert, R., Sturm, M., Haack, T.B., Schelling, Y., Mahajnah, M., Sharkia, R., Azem, A., Balousha, G., Ghanem, Z., et al. (2020). First-line exome sequencing in Palestinian and Israeli Arabs with neurological disorders is efficient and facilitates disease gene discovery. *Eur. J. Hum. Genet.* 28, 1034–1043.
52. Hiraide, T., Kubota, K., Kono, Y., Watanabe, S., Matsubayashi, T., Nakashima, M., Kaname, T., Fukao, T., Shimozaawa, N., Ogata, T., and Saitu, H. (2020). POLR3A variants in striatal involvement without diffuse hypomyelination. *Brain Dev.* 42, 363–368.
53. Hiraide, T., Nakashima, M., Ikeda, T., Tanaka, D., Osaka, H., and Saitu, H. (2020). Identification of a deep intronic POLR3A variant causing inclusion of a pseudoexon derived

- from an Alu element in Pol III-related leukodystrophy. *J. Hum. Genet.* 65, 921–925.
54. Infante, J., Serrano-Cárdenas, K.M., Corral-Juan, M., Farré, X., Sánchez, I., de Lucas, E.M., García, A., Martín-Gurpegui, J.L., Berciano, J., and Matilla-Dueñas, A. (2020). POLR3A-related spastic ataxia: new mutations and a look into the phenotype. *J. Neurol.* 267, 324–330.
 55. Jay, A.M., Conway, R.L., Thiffault, I., Saunders, C., Farrow, E., Adams, J., and Toriello, H.V. (2016). Neonatal progeroid syndrome associated with biallelic truncating variants in POLR3A. *Am. J. Med. Genet.* 170, 3343–3346.
 56. Ji, H., Li, D., Wu, Y., Zhang, Q., Gu, Q., Xie, H., Ji, T., Wang, H., Zhao, L., Zhao, H., et al. (2018). Hypomyelinating disorders in China: The clinical and genetic heterogeneity in 119 patients. *PLoS One* 13, e0188869. (no pagination).
 57. Khalifa, M., and Naffaa, L. (2015). Exome sequencing reveals a novel WDR45 frameshift mutation and inherited POLR3A heterozygous variants in a female with a complex phenotype and mixed brain MRI findings. *Eur. J. Med. Genet.* 58, 381–386.
 58. Khan, A., Al Shamsi, B., Al Shehhi, M., Kashgari, A.A., Al Balushi, A., Al Dihan, F.A., Alghamdi, M.A., Manal, A., González-Álvarez, A.C., Arold, S.T., and Eyaid, W. (2024). Further delineation of Wiedemann-Rautenstrauch syndrome linked with POLR3A. *Mol. Genet. Genomic Med.* 12, e2274.
 59. Kovalskaia, V.A., Kungurtseva, A.L., Bostanova, F.M., Vasiliev, P.A., Tabakov, V.Y., Orlova, M.D., Povolotskaya, I.S., Novoselova, O.G., Bikanov, R.A., Akhyamova, M.A., et al. (2024). The Genetic Basis of the First Patient with Wiedemann-Rautenstrauch Syndrome in the Russian Federation. *Genes* 15, 180.
 60. Kunii, M., Doi, H., Ishii, Y., Ohba, C., Tanaka, K., Tada, M., Fukai, R., Hashiguchi, S., Kishida, H., Ueda, N., et al. (2018). Genetic analysis of adult leukoencephalopathy patients using a custom-designed gene panel. *Clin. Genet.* 94, 232–238.
 61. Kyle, K., Mason, X., Bordelon, Y., Pouratian, N., and Bronstein, J. (2021). Adult onset POLR3A leukodystrophy presenting with parkinsonism treated with pallidal deep brain stimulation. *Parkinsonism Relat. Disorders* 85, 23–25.
 62. La Piana, R., Cayami, F.K., Tran, L.T., Guerrero, K., van Spaendonk, R., Öunap, K., Pajusalu, S., Haack, T., Wassmer, E., Timmann, D., et al. (2016). Diffuse hypomyelination is not obligate for POLR3-related disorders. *Neurology* 86, 1622–1626.
 63. Ledesma, P.A., Guerra, J.C., Burbano, M., Procel, P., and Pedroza, L.A. (2019). Whole exome sequencing in a child with acute disseminated encephalomyelitis, optic neuritis, and periodic fever syndrome: a case report. *J. Med. Case Rep.* 13, 368.
 64. Lessel, D., Ozel, A.B., Campbell, S.E., Saadi, A., Arlt, M.F., McSweeney, K.M., Plaiasu, V., Szakszon, K., Szöllös, A., Rusu, C., et al. (2018). Analyses of LMNA-negative juvenile progeroid cases confirms biallelic POLR3A mutations in Wiedemann-Rautenstrauch-like syndrome and expands the phenotypic spectrum of PYCR1 mutations. *Hum. Genet.* 137, 921–939.
 65. Lessel, D., Rading, K., Campbell, S.E., Thiele, H., Altmüller, J., Gordon, L.B., and Kubisch, C. (2022). A novel homozygous synonymous variant further expands the phenotypic spectrum of POLR3A-related pathologies. *Am. J. Med. Genet.* 188, 216–223.
 66. Lynch, D.S., Rodrigues Brandão de Paiva, A., Zhang, W.J., Bugiardini, E., Freua, F., Tavares Lucato, L., Macedo-Souza, L.I., Lakshmanan, R., Kinsella, J.A., Merwick, A., et al. (2017). Clinical and genetic characterization of leukoencephalopathies in adults. *Brain* 140, 1204–1211.
 67. Macaron, G., Samaan, S., Cohen, J.A., and Nadjar, Y. (2019). Genetic findings in adolescent and adult-onset leukodystrophies with hypomyelinating features. *J. Neurol. Neurosurg. Psychiatry* 90, 836–838.
 68. Majethia, P., and Girisha, K.M. (2021). Wiedemann-Rautenstrauch syndrome in an Indian patient with biallelic pathogenic variants in POLR3A. *Am. J. Med. Genet.* 185, 1602–1605.
 69. Maltese, P.E., Paolacci, S., Manara, E., Marceddu, G., Beccari, T., Ergoren, M.C., and Bertelli, M. (2018). Use of exome sequencing in identifying genes responsible for rare genetic diseases. *J. Biotechnol.* 280, S7.
 70. McKenna, M.C., O'Connor, A., Lockhart, A., Bogdanova-Mihaylova, P., Brett, F., Langan, Y., Meaney, J., Costigan, D., Doherty, C.P., Bede, P., et al. (2024). POLR3A-related disorders: expanding the clinical phenotype. *J. Neurol.* 271, 3635–3638.
 71. Midori, K., Hatanaka, Y., Kanbayashi, T., Okuma, H., Sonoo, M., Saitsu, H., and Matsumoto, N. (2014). A case report of 4h syndrome probably caused by a heterozygous abnormality of the POLR3A gene with preserved intellectual function. In *Neurology Conference: 66th American Academy of Neurology Annual Meeting*, AAN 82.
 72. Minnerop, M., Kurzwelly, D., Wagner, H., Soehn, A.S., Reichbauer, J., Tao, F., Rattay, T.W., Peitz, M., Rehbach, K., Giorgetti, A., et al. (2017). Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. *Brain* 140, 1561–1578.
 73. Monteiro, G.C., Margarit, B.P., Celi, J.M.C., Jiménez, D.E.B., Cristobal, J.H., Izquierdo, A.Y., Pujol, A., and Sales, M.R. (2020). Rare cause of Hypomyelinating Leukodystrophy type 7: "Gly672Glu homozygous variant of the POLR3A gene". *Eur. J. Neurol.* 27, 960.
 74. Montenegro, L.R., Freitas, M.R., Trabarch, E.B., Kok, F., Latronico, A.C., and Silveira, L.G. (2013). Mutational analysis of POLR3A and POLR3B genes in patients with 4H syndrome and isolated hypogonadotropic hypogonadism: Is there a link between these two conditions? *Endocr. Rev.* 34, i397.
 75. Montenegro, L.R., Freitas, M.R., Trabarch, E.B., Kok, F., Latronico, A.C., and Silveira, L.G. (2013). Novel rare variants in POLR3A and POLR3B genes identified in 4H syndrome patients with and without isolated hypogonadotropic hypogonadism. *Horm. Res. Paediatr.* 80, 36–37.
 76. Moon, B., Kim, M., Kim, H.J., Cho, J.S., Son, H.J., Lim, B.C., Kim, K.J., Chae, J.H., and Kim, S.Y. (2023). Biallelic POLR3A variants cause Wiedemann-Rautenstrauch syndrome with atypical brain involvement. *Clin. Exp. Pediatr.* 66, 142–144.
 77. Morales, L.C., Arboleda, G., Rodríguez, Y., Forero, D.A., Ramírez, N., Yunis, J.J., and Arboleda, H. (2009). Absence of Lamin A/C gene mutations in four Wiedemann-Rautenstrauch syndrome patients. *Am. J. Med. Genet.* 149a, 2695–2699.
 78. Morales-Rosado, J.A., Macke, E.L., Cousin, M.A., Oliver, G. R., Dhamija, R., and Klee, E.W. (2020). Interpretation challenges of novel dual-class missense and splice-impacting

- variant in POLR3A-related late-onset hereditary spastic ataxia. *Mol. Genet. Genomic Med.* 8, e1341.
79. Mrabet, S., Kraoua, I., Dorboz, I., Ben Rhouma, H., Klaa, H., Ben Achour, N., Rouissi, A., Abdelhak, S., Tanguy, O., and Ben Youssef Turki, I. (2015). POLR3A mutation: A rare cause of hypomyelinating leukodystrophy. *Eur. J. Neurol.* 1, 232.
80. Musumeci, A., Calì, F., Scuderi, C., Vinci, M., Vitello, G.A., Musumeci, S.A., Chiavetta, V., Federico, C., Amore, G., Saccone, S., et al. (2022). Identification of a Novel Missense Mutation of POLR3A Gene in a Cohort of Sicilian Patients with Leukodystrophy. *Biomedicines* 10, 2276.
81. Neocleous, V., Fanis, P., Toumba, M., Tanteles, G.A., Schiza, M., Cinarli, F., Nicolaides, N.C., Oulas, A., Spyrou, G.M., Mantzoros, C.S., et al. (2020). GnRH Deficient Patients With Congenital Hypogonadotropic Hypogonadism: Novel Genetic Findings in ANOS1, RNF216, WDR11, FGFR1, CHD7, and POLR3A Genes in a Case Series and Review of the Literature. *Front. Endocrinol.* 11, 626.
82. Nikkhah, A., and Rezakhani, S. (2022). Developmental regression and movement disorder as a phenotypic variant of POLR3A Mutation-Case report. *Clin. Case Rep.* 10, e6556.
83. Ogunjimi, B., Zhang, S.Y., Sørensen, K.B., Skipper, K.A., Carter-Timofte, M., Kerner, G., Luecke, S., Prabakaran, T., Cai, Y., Meester, J., et al. (2017). Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections. *J. Clin. Investig.* 127, 3543–3556.
84. Paolacci, S., Bertola, D., Franco, J., Mohammed, S., Tartaglia, M., Wollnik, B., and Hennekam, R.C. (2017). Wiedemann–Rautenstrauch syndrome: A phenotype analysis. *Am. J. Med. Genet.* 173, 1763–1772.
85. Paolacci, S., Li, Y., Agolini, E., Bellacchio, E., Arboleda-Bustos, C.E., Carrero, D., Bertola, D., Al-Gazali, L., Alders, M., Altmüller, J., et al. (2018). Specific combinations of biallelic POLR3A variants cause Wiedemann-Rautenstrauch syndrome. *J. Med. Genet.* 55, 837–846.
86. Patel, R., Witek, N., and Afshari, M. (2020). Adult-onset POLR3 leukodystrophy: A case report. *Mov. Disord. Clin. Pract.* 7, S90.
87. Peng, Q., Zhang, Y., Xian, B., Wu, L., Ding, J., Ding, W., Zhang, X., Ding, B., Li, D., Wu, J., et al. (2022). A synonymous variant contributes to a rare Wiedemann-Rautenstrauch syndrome complicated with mild anemia via affecting pre-mRNA splicing. *Front. Mol. Neurosci.* 15, 1026530.
88. Perrier, S., Gauquelin, L., Fallet-Bianco, C., Dishop, M.K., Michell-Robinson, M.A., Tran, L.T., Guerrero, K., Darbelli, L., Srouf, M., Petrecca, K., et al. (2020). Expanding the phenotypic and molecular spectrum of RNA polymerase III-related leukodystrophy. *Neurol. Genet.* 6, e425.
89. Perrier, S., Gauquelin, L., Wambach, J.A., and Bernard, G. (2022). Distinguishing severe phenotypes associated with pathogenic variants in POLR3A. *Am. J. Med. Genet.* 188, 708–712.
90. Potic, A., Brais, B., Choquet, K., Schiffmann, R., and Bernard, G. (2012). 4H syndrome with late-onset growth hormone deficiency caused by POLR3A mutations. *Arch. Neurol.* 69, 920–923.
91. Potic, A., Popovic, V., Ostojic, J., Pekic, S., Kozic, D., Guerrero, K., Schiffmann, R., and Bernard, G. (2015). Neurogenic bladder and neuroendocrine abnormalities in Pol III-related leukodystrophy. *BMC Neurol.* 15, 22.
92. Rautenstrauch, T., and Snigula, F. (1977). Progeria: a cell culture study and clinical report of familial incidence. *Eur. J. Pediatr.* 124, 101–111.
93. Ruan, D.D., Ruan, X.L., Wang, R.L., Lin, X.F., Zhang, Y.P., Lin, B., Li, S.J., Wu, M., Chen, Q., Zhang, J.H., et al. (2024). Clinical phenotype and genetic function analysis of a family with hypomyelinating leukodystrophy-7 caused by POLR3A mutation. *Sci. Rep.* 14, 7638.
94. Ruggiero, L., Iovino, A., Dubbioso, R., Cocozza, S., Trovato, R., Aruta, F., Pontillo, G., Barghigiani, M., Brunetti, A., Santorelli, F.M., et al. (2020). Multimodal evaluation of an Italian family with a hereditary spastic paraplegia and POLR3A mutations. *Ann. Clin. Transl. Neurol.* 7, 2326–2331.
95. Rydning, S.L., Koht, J., Sheng, Y., Sowa, P., Hjorthaug, H.S., Wedding, I.M., Erichsen, A.K., Hovden, I.A., Backe, P.H., Tallaksen, C.M.E., et al. (2019). Biallelic POLR3A variants confirmed as a frequent cause of hereditary ataxia and spastic paraparesis. *Brain* 142, e12.
96. Saitsu, H., Osaka, H., Sasaki, M., Takanashi, J.I., Hamada, K., Yamashita, A., Shibayama, H., Shiina, M., Kondo, Y., Nishiyama, K., et al. (2011). Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy. *Am. J. Hum. Genet.* 89, 644–651.
97. Schobers, G., Pennings, M., de Vries, J., Kwint, M., van Reeuwijk, J., Corominas Galbany, J., van Beek, R., Kamping, E., Timmermans, R., Kamsteeg, E.-J., et al. (2024). Uncovering recessive alleles in rare Mendelian disorders by genome sequencing of 174 individuals with monoallelic pathogenic variants. *Eur. J. Hum. Genet.* 33, 56–64.
98. Schüle, R., Timmann, D., Erasmus, C.E., Reichbauer, J., Wayand, M., van de Warrenburg, B., Schöls, L., Wilke, C., Bevilacqua, A., Zuchner, S., et al. (2021). Solving unsolved rare neurological diseases—a Solve-RD viewpoint. *Eur. J. Hum. Genet.* 29, 1332–1336.
99. Shima, T., Fujimoto, T., Miyazaki, T., and Nonaka, F. (2016). A Case of Pol III-related Leukodystrophy with Homozygous Mutation in POLR3A. *Brain Nerve* 68, 1393–1397.
100. Shimojima, K., Shimada, S., Tamasaki, A., Akaboshi, S., Komoi, Y., Saito, A., Furukawa, T., and Yamamoto, T. (2014). Novel compound heterozygous mutations of POLR3A revealed by whole-exome sequencing in a patient with hypomyelination. *Brain Dev.* 36, 315–321.
101. Sigatullina, M., O'Callaghan, M., Gonzalez, J., Baquero, M., Marmiesse, A., and Armstrong, J. (2014). Heterozygote mutation in POLR3A and AIMP1 genes in a patient with hypomyelinating leukodystrophy. *Eur. J. Neurol.* 21, 252.
102. Sun, L., Lin, W., Meng, H., Zhang, W., and Hou, S. (2023). A Chinese patient with POLR3A-related leukodystrophy: a case report and literature review. *Front. Neurol.* 14, 1269237.
103. Sytsma, T.M., Chen, D.H., Rolf, B., Dorschner, M., Jayadev, S., Keene, C.D., Zhang, J., Bird, T.D., and Latimer, C.S. (2022). Spinal cord-predominant neuropathology in an adult-onset case of POLR3A-related spastic ataxia. *Neuropathology* 42, 58–65.
104. Tailland, M., Gonzalez, V., Prin, P., Carra-Dallière, C., Ayri-gnac, X., and Labauge, P. (2021). POLR3-related disorder revealed by movement disorders. *Rev. Neurol.* 177, 328–330.
105. Tamura, A., Niwa, A., Ii, Y., Sasaki, R., Tomimoto, H., and Saitsu, H. (2013). A case of hypomyelinating leukodystrophy

- with new homozygous mutation in POLR3A. *Rinsho Shinkeigaku* 53, 624–629.
106. Temel, S.G., Ergoren, M.C., Manara, E., Paolacci, S., Tuncel, G., Gul, S., and Bertelli, M. (2020). Unique combination and in silico modeling of biallelic POLR3A variants as a cause of Wiedemann-Rautenstrauch syndrome. *Eur. J. Hum. Genet.* 28, 1675–1680.
 107. Terao, Y., Saitsu, H., Segawa, M., Kondo, Y., Sakamoto, K., Matsumoto, N., Tsuji, S., and Nomura, Y. (2012). Diffuse central hypomyelination presenting as 4H syndrome caused by compound heterozygous mutations in POLR3A encoding the catalytic subunit of polymerase III. *JNeuroSci* 320, 102–105.
 108. Tewari, V.V., Mehta, R., Sreedhar, C.M., Tewari, K., Mohammad, A., Gupta, N., Gulati, S., and Kabra, M. (2018). A novel homozygous mutation in POLR3A gene causing 4H syndrome: a case report. *BMC Pediatr.* 18, 126.
 109. Timmons, M., Tsokos, M., Asab, M.A., Seminara, S.B., Zirzow, G.C., Kaneski, C.R., Heiss, J.D., van der Knaap, M.S., Vanier, M.T., Schiffmann, R., and Wong, K. (2006). Peripheral and central hypomyelination with hypogonadotropic hypogonadism and hypodontia. *Neurology* 67, 2066–2069.
 110. Travaglini, L., Aiello, C., Stregapede, F., D'Amico, A., Alesi, V., Ciolfi, A., Bruselles, A., Catteruccia, M., Pizzi, S., Zanni, G., et al. (2018). The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes. *Neurogenetics* 19, 111–121.
 111. Uygun, Ö., Gündüz, T., Eraksoy, M., and Kürtüncü, M. (2020). Adult-onset 4H leukodystrophy: a case presentation and review of the literature. *Acta Neurol. Belg.* 120, 1461–1462.
 112. Venkatraman, A., Hamm, J.A., Shaefer, A., Rinker, J., and Nozaki, K. (2016). Leukodystrophy and neurogenic EMG changes associated with variants in POLR3A and PMP22. In *Neurology Conference: 68th American Academy of Neurology Annual Meeting*, AAN 86.
 113. Vázquez-López, M., Ruiz-Martín, Y., de Castro-Castro, P., Garzo-Fernández, C., Martín-del Valle, F., and Márquez-de la Plata, L. (2008). Central hypomyelination, hypogonadotropic hypogonadism and hypodontia: a new leukodystrophy. *Rev. Neurol.* 47, 204–208.
 114. Wambach, J.A., Wegner, D.J., Patni, N., Kircher, M., Willing, M.C., Baldrige, D., Xing, C., Agarwal, A.K., Vergano, S.A.S., Patel, C., et al. (2018). Bi-allelic POLR3A Loss-of-Function Variants Cause Autosomal-Recessive Wiedemann-Rautenstrauch Syndrome. *Am. J. Hum. Genet.* 103, 968–975.
 115. Wang, C., Wang, S., Xie, H., and Yang, S. (2022). Clinical and imaging characteristics of 4H syndrome: A case report. *CNS Neurosci. Ther.* 28, 458–460.
 116. Wolf, N.I., Harting, I., Boltshauser, E., Wiegand, G., Koch, M.J., Schmitt-Mechelke, T., Martin, E., Zschocke, J., Uhlenberg, B., Hoffmann, G.F., et al. (2005). Leukoencephalopathy with ataxia, hypodontia, and hypomyelination. *Neurology* 64, 1461–1464.
 117. Wolf, N.I., Harting, I., Innes, A.M., Patzer, S., Zeitler, P., Schneider, A., Wolff, A., Baier, K., Zschocke, J., Ebinger, F., et al. (2007). Ataxia, delayed dentition and hypomyelination: a novel leukoencephalopathy. *Neuropediatrics* 38, 64–70.
 118. Wolf, N.I., Vanderver, A., van Spaendonk, R.M.L., Schiffmann, R., Brais, B., Bugiani, M., Sistermans, E., Catsman-Berrevvoets, C., Kros, J.M., Pinto, P.S., et al. (2014). Clinical spectrum of 4H leukodystrophy caused by POLR3A and POLR3B mutations. *Neurology* 83, 1898–1905.
 119. Wu, S., Bai, Z., Dong, X., Yang, D., Chen, H., Hua, J., Zhou, L., and Lv, H. (2019). Novel mutations of the POLR3A gene caused POLR3-related leukodystrophy in a Chinese family: a case report. *BMC Pediatr.* 19, 289.
 120. Yang, Y.M., Zhao, Z.M., Jia, Y.L., Jia, Y.J., Han, N., and Wang, J.H. (2019). A 42-year-old woman with 4H leukodystrophy caused by a homozygous mutation in POLR3A gene. *Chin. Med. J.* 132, 1879–1880.
 121. Yang, F., Sun, H., Yang, Y., Wang, Y., Dai, S., Lin, Z., Shen, Y., and Liu, H. (2023). Identification of POLR3B biallelic mutations-associated hypomyelinating leukodystrophy-8 in two siblings. *Clin. Genet.* 103, 596–602.
 122. Yau, W.Y., Ashton, C., Mulroy, E., Foltynie, T., Limousin, P., Vandrovcova, J., Verma, K.P., Stell, R., Davis, M., and Lamont, P. (2024). POLR3A-related disorders: From spastic ataxia to generalised dystonia and long-term efficacy of deep brain stimulation. *Ann. Clin. Transl. Neurol.* 11, 1636–1642.
 123. Yoon Han, J., Gon Cho, Y., Park, J., and Jang, W. (2022). A novel variant of the POLR3A gene in a patient with hypomyelinating POLR3-related leukodystrophy. *Clin. Chim. Acta* 533, 15–21.
 124. Yu, C., Xie, B., Zhao, Z., Zhao, S., Liu, L., Cheng, X., Li, X., Cao, B., Shao, J., Chen, J., et al. (2021). Whole Exome Sequencing Uncovered the Genetic Architecture of Growth Hormone Deficiency Patients. *Front. Endocrinol.* 12, 711991.
 125. Zanette, V., Reyes, A., Johnson, M., do Valle, D., Robinson, A.J., Monteiro, V., Telles, B.A., L R Souza, R., S F Santos, M.L., Benincá, C., and Zeviani, M. (2020). Neurodevelopmental regression, severe generalized dystonia, and metabolic acidosis caused by POLR3A mutations. *Neurol. Genet.* 6, e521.
 126. Zea Vera, A., Bruce, A., Larsh, T.R., Jordan, Z., Brüggemann, N., Westenberger, A., Espay, A.J., Gilbert, D.L., and Wu, S. W. (2023). Spectrum of Pediatric to Early Adulthood POLR3A-Associated Movement Disorders. *Mov. Disord. Clin. Pract.* 10, 316–322.
 127. Zhang, J., Tang, S.Y., Zhu, X.B., Li, P., Lu, J.Q., Cong, J.S., Wang, L.B., Zhang, F., and Li, Z. (2021). Whole exome sequencing and trio analysis to broaden the variant spectrum of genes in idiopathic hypogonadotropic hypogonadism. *Asian J. Androl.* 23, 288–293.
 128. de Assis Pereira Matos, P.C.A., Gama, M.T.D., Bezerra, M.L. E., da Rocha, A.J., Barsottini, O.G.P., and Pedroso, J.L. (2020). POLR3A-Related Disorder Presenting with Late-Onset Dystonia and Spastic Paraplegia. *Mov. Disord. Clin. Pract.* 7, 467–469.
 129. Ando, M., Higuchi, Y., Yuan, J.H., Yoshimura, A., Kitao, R., Morimoto, T., Taniguchi, T., Takeuchi, M., Takei, J., Hiramatsu, Y., et al. (2022). Novel *de novo* POLR3B mutations responsible for demyelinating Charcot-Marie-Tooth disease in Japan. *Ann. Clin. Transl. Neurol.* 9, 747–755.
 130. Bai, H., Li, D., Zheng, Y., and Jiang, X. (2022). Case report: Biallelic variants in POLR3B gene lead to 4H leukodystrophy from the study of brother and sister. *Medicine (Baltim.)* 101, e30350.

131. Battini, R., Bertelloni, S., Astrea, G., Casarano, M., Travalgini, L., Baroncelli, G., Pasquariello, R., Bertini, E., and Cioni, G. (2015). Longitudinal follow up of a boy affected by Pol III-related leukodystrophy: a detailed phenotype description. *BMC Med. Genet.* 16, 53.
132. M Borella, L.F., Pereira, D.A., and Reis, F. (2023). Neuroimaging of POLR3B-related Hypomyelinating Leukodystrophy. *Neurol. India* 71, 1098–1099.
133. Cayami, F.K., La Piana, R., van Spaendonk, R.M.L., Nickel, M., Bley, A., Guerrero, K., Tran, L.T., van der Knaap, M.S., Bernard, G., and Wolf, N.I. (2015). POLR3A and POLR3B Mutations in Unclassified Hypomyelination. *Neuropediatrics* 46, 221–228.
134. Colona, V.L., Bertini, E., Digilio, M.C., D'Amico, A., Novelli, A., Pro, S., Pisaneschi, E., and Nicita, F. (2023). A New Case of Autosomal-Dominant POLR3B-Related Disorder: Widening Genotypic and Phenotypic Spectrum. *Brain Sci.* 13, 1567.
135. Darvish, H., Azcona, L.J., Tafakhori, A., Mesias, R., Ahmadi-fard, A., Sanchez, E., Habibi, A., Alehabib, E., Johari, A.H., Emamalizadeh, B., et al. (2020). Phenotypic and genotypic characterization of families with complex intellectual disability identified pathogenic genetic variations in known and novel disease genes. *Sci. Rep.* 10, 968.
136. De Dominicis, A., Stregapede, F., Colona, V.L., Nicita, F., Sartorelli, J., Sparascio, F.P., Terracciano, A., Novelli, A., Specchio, N., Bertini, E.S., and Trivisano, M. (2024). POLR3B *de novo* variants are a rare cause of infantile myoclonic epilepsy. *Seizure* 121, 141–146.
137. DeGasperis, S.M., Bernard, G., Wolf, N.I., Miller, E., and Pohl, D. (2020). 4H leukodystrophy: Mild clinical phenotype and comorbidity with multiple sclerosis. *Neurol. Genet.* 6, e409.
138. Djordjevic, D., Pinard, M., Gauthier, M.S., Smith-Hicks, C., Hoffman, T.L., Wolf, N.I., Oegema, R., van Binsbergen, E., Baskin, B., Bernard, G., et al. (2021). De novo variants in POLR3B cause ataxia, spasticity, and demyelinating neuropathy. *Am. J. Hum. Genet.* 108, 186–193.
139. Fukuda, M., Morimoto, T., Suzuki, Y., Kida, K., and Ohnishi, A. (2000). Congenital neuropathy with the absence of large myelinated fibers. *Pediatr. Neurol.* 23, 349–351.
140. Gach, A., Pinkier, I., Wysocka, U., Sałacińska, K., Salachna, D., Szarras-Czapnik, M., Pietrzyk, A., Sakowicz, A., Nykel, A., Rutkowska, L., et al. (2022). New findings in oligogenic inheritance of congenital hypogonadotropic hypogonadism. *Arch. Med. Sci.* 18, 353–364.
141. Geroldi, A., Tozza, S., Fiorillo, C., Nolano, M., Fossa, P., Vitale, F., Domi, R., Gaudio, A., Mammi, A., Patrone, S., et al. (2023). A novel *de novo* variant in POLR3B gene associated with a primary axonal involvement of the largest nerve fibers. *J. Peripher. Nerv. Syst.* 28, 620–628.
142. Ghomid, J., Petit, F., Boute-Benejean, O., Frenois, F., Cartigny, M., Vanlerberghe, C., Smol, T., Caumes, R., de Roux, N., and Manouvrier-Hanu, S. (2017). Cerebellar hypoplasia with endosteal sclerosis is a POLR3-related disorder. *Eur. J. Hum. Genet.* 25, 1011–1014.
143. Gutierrez, M., Thiffault, I., Guerrero, K., Martos-Moreno, G. Á., Tran, L.T., Benko, W., van der Knaap, M.S., van Spaendonk, R.M.L., Wolf, N.I., and Bernard, G. (2015). Large exonic deletions in POLR3B gene cause POLR3-related leukodystrophy. *Orphanet J. Rare Dis.* 10, 69.
144. Hamdan, Z., and Alasmar, D. (2023). Uncertain significance mutation in the POLR3B gene in a Syrian boy with leukodystrophy: a case report. *Ann. Med. Surg.* 85, 4126–4130.
145. Haneda, A., Hoots, J.K., Hagy, H.A., and Lacy, M. (2024). Case report: Neuropsychological assessment in a patient with 4H leukodystrophy. *Clin. Neuropsychol.* 38, 1272–1289.
146. Jurkiewicz, E., Dunin-Wasowicz, D., Gieruszczak-Białek, D., Malczyk, K., Guerrero, K., Gutierrez, M., Tran, L., and Bernard, G. (2017). Recessive Mutations in POLR3B Encoding RNA Polymerase III Subunit Causing Diffuse Hypomyelination in Patients with 4H Leukodystrophy with Polymicrogyria and Cataracts. *Clin. Neuroradiol.* 27, 213–220.
147. Krygier, M., Kwarciany, M., Wasilewska, K., Pienkowski, V. M., Krawczyńska, N., Zielonka, D., Kosińska, J., Stawinski, P., Rudzińska-Bar, M., Boczarska-Jedynak, M., et al. (2019). A study in a Polish ataxia cohort indicates genetic heterogeneity and points to MTCL1 as a novel candidate gene. *Clin. Genet.* 95, 415–419.
148. Kulhánek, J., Brožová, K., Hansíková, H., Vondráčková, A., Stránecký, V., Šenkyřík, J., Kmoch, S., Zeman, J., Honzík, T., and Tesařová, M. (2019). POLR3B-associated leukodystrophy: clinical, neuroimaging and molecular-genetic analyses in four patients: clinical heterogeneity and novel mutations in POLR3B gene. *Neurol. Neurochir. Pol.* 53, 369–376.
149. Lin, Z., Liu, L., Li, X., Huang, S., Zhao, H., Zeng, S., Yang, H., Xie, Y., and Zhang, R. (2024). Phenotype-driven reanalysis reveals five novel pathogenic variants in 40 exome-negative families with Charcot-Marie-Tooth Disease. *J. Neurol.* 271, 497–503.
150. Mahdih, N., Soveizi, M., Tavasoli, A.R., Rabbani, A., Ashrafi, M.R., Kohlschütter, A., and Rabbani, B. (2021). Genetic testing of leukodystrophies unraveling extensive heterogeneity in a large cohort and report of five common diseases and 38 novel variants. *Sci. Rep.* 11, 3231.
151. Mattijssen, S., Kerkhofs, K., Stephen, J., Yang, A., Han, C.G., Tadafumi, Y., Iben, J.R., Mishra, S., Sakhawala, R.M., Ranjan, A., et al. (2024). A POLR3B-variant reveals a Pol III transcriptome response dependent on La protein/SSB. Preprint at bioRxiv. <https://doi.org/10.1101/2024.02.05.577363>.
152. Milovanova, N., Zakharova, E.Y., Mikhailova, S.V., Pechatnikova, N., and Fedonyk, I. (2014). Two possible new mutations of the POLR3B gene in Russian patients with hypomyelinating leukodystrophies. *J. Inherit. Metab. Dis.* 1, S173–S174.
153. Muirhead, K.J., Clause, A.R., Schlachetzki, Z., Dubbs, H., Perry, D.L., Hagelstrom, R.T., Taft, R.J., and Vanderver, A. (2021). Genome sequencing identifies three molecular diagnoses including a mosaic variant in the COL2A1 gene in an individual with Pol III-related leukodystrophy and Feingold syndrome. *Cold Spring Harb. Mol. Case Stud.* 7, a006143.
154. Najmabadi, H., Hu, H., Garshabi, M., Zemojtel, T., Abedini, S.S., Chen, W., Hosseini, M., Behjati, F., Haas, S., Jamali, P., et al. (2011). Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* 478, 57–63.
155. Ozgen, H.M., Overweg-Plandsoen, W.C.G., Bles-Pelk, J., Besselaar, P.P., and Hennekam, R.C.M. (2005). Cerebellar hypoplasia-endosteal sclerosis: a long term follow-up. *Am. J. Med. Genet.* 134a, 215–219.
156. Richards, M.R., Plummer, L., Chan, Y.M., Lippincott, M.F., Quinton, R., Kumanov, P., and Seminara, S.B. (2017). Phenotypic spectrum of POLR3B mutations: isolated

- hypogonadotropic hypogonadism without neurological or dental anomalies. *J. Med. Genet.* 54, 19–25.
157. Saghi, M., InanlooRahatloo, K., Alavi, A., Kahrizi, K., and Najmabadi, H. (2022). Intellectual disability associated with craniofacial dysmorphism due to POLR3B mutation and defect in spliceosomal machinery. *BMC Med. Genom.* 15, 89.
 158. Symonds, J.D., Park, K.L., Mignot, C., Macleod, S., Armstrong, M., Ashrafi, H., Bernard, G., Brown, K., Brunklaus, A., Callaghan, M., et al. (2024). POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic-astatic seizures and ataxia. *Epilepsia* 65, 3303–3323.
 159. Synofzik, M., Bernard, G., Lindig, T., and Gburek-Augustat, J. (2013). Teaching neuroimages: hypomyelinating leukodystrophy with hypodontia due to POLR3B: look into a leukodystrophy's mouth. *Neurology* 81, e145.
 160. Tetreault, M., Choquet, K., Orcesi, S., Tonduti, D., Balottin, U., Teichmann, M., Fribourg, S., Schiffmann, R., Brais, B., Vanderver, A., et al. (2011). Recessive mutations in POLR3B, encoding the second largest subunit of Pol III, cause a rare hypomyelinating leukodystrophy. *Am. J. Hum. Genet.* 89, 652–655.
 161. Verberne, E.A., Dalen Meurs, L., Wolf, N.I., and van Haelst, M.M. (2020). 4H leukodystrophy caused by a homozygous POLR3B mutation: Further delineation of the phenotype. *Am. J. Med. Genet.* 182, 1776–1779.
 162. Wu, S.W., Li, L., Feng, F., Wang, L., Kong, Y.Y., Liu, X.W., and Yin, C. (2021). Whole-exome sequencing reveals POLR3B variants associated with progeria-related Wiedemann-Rautenstrauch syndrome. *Ital. J. Pediatr.* 47, 160.
 163. Xue, Y.Y., Cheng, H.L., Dong, H.L., Yin, H.M., Yuan, Y., Meng, L.C., Wu, Z.Y., and Yu, H. (2021). A *de novo* variant of POLR3B causes demyelinating Charcot-Marie-Tooth disease in a Chinese patient: a case report. *BMC Neurol.* 21, 402.
 164. Yang, H.J., Park, G., Nam-Goong, I.S., Ahn, J.W., and Weon, Y.C. (2022). The First Korean Siblings With Adult-Onset 4H Leukodystrophy Related to Nonsynonymous POLR3B Mutations. *Neurol. Genet.* 8, e667.
 165. Yang, H., Wu, Z., Li, X., Huang, Y., Li, J., He, F., Feng, L., Xiao, B., and Tang, W. (2023). A novel variant of the POLR3A gene in a Chinese patient with POLR3-related leukodystrophy. *Neurol. Sci.* 44, 3363–3368.
 166. Zhang, L., and Peng, D. (2020). Clinical and genetic phenotypes of a patient with POLR3B gene-related hypomyelinating leukodystrophy and hypogonadism. [Chinese]. *Chin. J. Neurol.* 53, 746–752.
 167. Macintosh, J., Perrier, S., Pinard, M., Tran, L.T., Guerrero, K., Prasad, C., Prasad, A.N., Pastinen, T., Thiffault, I., Coulombe, B., and Bernard, G. (2023). Biallelic pathogenic variants in POLR3D alter tRNA transcription and cause a hypomyelinating leukodystrophy: A case report. *Front. Neurol.* 14, 1254140.
 168. Dorboz, I., Dumay-Odelot, H., Boussaid, K., Bouyacoub, Y., Barreau, P., Samaan, S., Jmel, H., Eymard-Pierre, E., Cances, C., Bar, C., et al. (2018). Mutation in POLR3K causes hypomyelinating leukodystrophy and abnormal ribosomal RNA regulation. *Neurol. Genet.* 4, e289.
 169. Perrier, S., Macintosh, J., Misiaszek, A.D., Lambert, G., Guerrero, K., Tran, L.T., Müller, C.W., Pastinen, T., Maegawa, G. H.B., Thiffault, I., and Bernard, G. (2024). Novel pathogenic variants in POLR3K cause POLR3-related leukodystrophy. *Hum. Mutat.* 2024, 8807171.
 170. Beauregard-Lacroix, E., Salián, S., Kim, H., Ehresmann, S., D'Amours, G., Gauthier, J., Saillour, V., Bernard, G., Mitchell, G.A., Soucy, J.F., et al. (2020). A variant of neonatal progeroid syndrome, or Wiedemann-Rautenstrauch syndrome, is associated with a nonsense variant in POLR3GL. *Eur. J. Hum. Genet.* 28, 461–468.
 171. Carter-Timofte, M.E., Hansen, A.F., Christiansen, M., Paludan, S.R., and Mogensen, T.H. (2019). Mutations in RNA Polymerase III genes and defective DNA sensing in adults with varicella-zoster virus CNS infection. *Gene Immun.* 20, 214–223.
 172. Carter-Timofte, M.E., Hansen, A.F., Mardahl, M., Fribourg, S., Rapaport, F., Zhang, S.Y., Casanova, J.L., Paludan, S.R., Christiansen, M., Larsen, C.S., and Mogensen, T.H. (2018). Varicella-zoster virus CNS vasculitis and RNA polymerase III gene mutation in identical twins. *Neurol. Neuroimmunol. Neuroinflamm.* 5, e500.
 173. Ceylan, A.C., Sahin, I., Erdem, H.B., Kayhan, G., Simsek-Kiper, P.O., Utine, G.E., Percin, F., Boduroglu, K., and Alikasifoglu, M. (2019). An eight-case 1q21 region series: novel aberrations and clinical variability with new features. *J. Intellect. Disabil. Res.* 63, 548–557.
 174. Dinov, D., Vorona, G., and Harper, A. (2021). Child Neurology: Hypotonia and Delayed Teeth Eruption in a 2-Year-Old Girl. *Neurology* 97, 875–878.
 175. Engels, H., Wohlleber, E., Zink, A., Hoyer, J., Ludwig, K.U., Brockschmidt, F.F., Wiczorek, D., Moog, U., Hellmann-Mersch, B., Weber, R.G., et al. (2009). A novel microdeletion syndrome involving 5q14.3-q15: Clinical and molecular cytogenetic characterization of three patients. *Eur. J. Hum. Genet.* 17, 1592–1599.
 176. Franca, M.M., Han, X., Funari, M.F.A., Lerario, A.M., Nishi, M.Y., Fontenele, E.G.P., Domenice, S., Jorge, A.A.L., Garcia-Galiano, D., Elias, C.F., and Mendonca, B.B. (2019). Exome Sequencing Reveals the POLR3H Gene as a Novel Cause of Primary Ovarian Insufficiency. *J. Clin. Endocrinol. Metab.* 104, 2827–2841.
 177. Giampietro, P.F., Armstrong, L., Stoddard, A., Blank, R.D., Livingston, J., Raggio, C.L., Rasmussen, K., Pickart, M., Loria, R., Turner, A., et al. (2015). Whole exome sequencing identifies a POLR1D mutation segregating in a father and two daughters with findings of Klippel-Feil and Treacher Collins syndromes. *Am. J. Med. Genet.* 167a, 95–102.
 178. Gu, J., Sreenath Nagamani, S.C., Hopwood, V.L., Sanchez, B., Saeidinejad, Y., Ou, Z., Peacock, S., Grange, D.K., Stankiewicz, P., and Cheung, S.W. (2011). Complex Genomic Rearrangement of Chromosome 16p13.3 Detected by Array Comparative Genomic Hybridization in a Patient With Multiple Congenital Anomalies, Dysmorphic Craniofacial Features, and Developmental Delay. *Am. J. Med. Genet.* 155A, 2589–2592.
 179. Guo, Y., Ning, F., Wang, G., Li, X., Liu, J., Yuan, Y., and Dai, P. (2020). Retrospective study of Langerhans cell histiocytosis in ear, nose and neck. *Am. J. Otolaryngol.* 41, 102369.
 180. Li, X., Su, Y., Huang, S., Gao, B., Zhang, D., Wang, X., Gao, Q., Pang, H., Zhao, Y., Yuan, Y., and Dai, P. (2019). Genotype-phenotype variability in Chinese cases of Treacher Collins syndrome. *Acta Otolaryngol.* 139, 567–575.
 181. Lu, M., Yang, B., Chen, Z., Jiang, H., and Pan, B. (2022). Phenotype Analysis and Genetic Study of Chinese Patients

- With Treacher Collins Syndrome. *Cleft Palate Craniofac. J.* 59, 1038–1047.
182. Ramanathan, A., Weintraub, M., Orlovetskie, N., Serruya, R., Mani, D., Marcu, O., Stepensky, P., Weisblum, Y., Djian, E., Shaag, A., et al. (2020). A mutation in POLR3E impairs antiviral immune response and RNA polymerase III. *Proc. Natl. Acad. Sci. USA* 117, 22113–22121.
 183. Schaefer, E., Collet, C., Genevieve, D., Vincent, M., Lohmann, D.R., Sanchez, E., Bolender, C., Eliot, M.M., Nürnberg, G., Passos-Bueno, M.R., et al. (2014). Autosomal recessive POLR1D mutation with decrease of TCOF1 mRNA is responsible for Treacher Collins syndrome. *Genet. Med.* 16, 720–724.
 184. Shenoy, R.D., Shetty, V., Dheedene, A., Menten, B., Pandiyanda Nanjappa, D., Chakraborty, G., Sips, P., de Paepe, A., Callewaert, B., and Chakraborty, A. (2022). Phenotypic and Molecular Heterogeneity in Mandibulofacial Dysostoses: A Case Series From India. *Cleft Palate Craniofac. J.* 59, 1346–1351.
 185. Terhal, P.A., Vlaar, J.M., Middelkamp, S., Nievelstein, R.A.J., Nikkels, P.G.J., Ross, J., Créton, M., Bos, J.W., Voskuil-Kerkhof, E.S.M., Cuppen, E., et al. (2020). Biallelic variants in POLR3GL cause endosteal hyperostosis and oligodontia. *Eur. J. Hum. Genet.* 28, 31–39.
 186. Vincent, M., Geneviève, D., Ostertag, A., Marlin, S., Lacombe, D., Martin-Coignard, D., Coubes, C., David, A., Lyonnet, S., Vilain, C., et al. (2016). Treacher Collins syndrome: a clinical and molecular study based on a large series of patients. *Genet. Med.* 18, 49–56.
 187. Yang, Y.D., Zhen, L., and Li, D.Z. (2022). Intrafamilial Phenotypic Heterogeneity in a Chinese Family with a POLR1D p.Q31Rfs*10 Variant: A Challenge in Prenatal Diagnosis. *Mol. Syndromol.* 13, 328–331.
 188. Khan, H., Harripaul, A., Mikhailov, A., Herzi, S., Bowers, S., Ayub, M., Shabbir, M.I., and Vincent, J.B. (2024). Biallelic variants identified in 36 Pakistani families and trios with autism spectrum disorder. *Sci. Rep.* 14, 9230.
 189. Antal, G., Zsigmond, A., Till, Á., Szabó, A., Maász, A., Bene, J., and Hadzsiev, K. (2024). Molecular and Clinical Heterogeneity in Hungarian Patients with Treacher Collins Syndrome—Identification of Two Novel Mutations by Next-Generation Sequencing. *Int. J. Mol. Sci.* 25, 11400.
 190. Sun, S.P., Zuo, B., He, W.L., Wang, H.J., Xu, H.E., and Lu, W. (2024). [Treacher Collins Syndrome 2 caused by a novel pathogenic variant in PLOR1D: clinical report and literature review]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 59, 934–940.
 191. Elbagoury, N.M., Nabil, A., Abdel-Aleem, A.F., Habib, A., Ashaat, E.A., Sharaf-Eldin, W.E., and Esswai, M.L. (2023). Clinical and molecular study of Egyptian patients with Treacher Collins syndrome. *Clin. Dysmorphol.* 32, 156–161.
 192. Zhou, S., and Van Bortle, K. (2023). The Pol III transcriptome: Basic features, recurrent patterns, and emerging roles in cancer. *Wiley Interdiscip. Rev. RNA* 14, e1782.
 193. Abascal-Palacios, G., Ramsay, E.P., Beuron, F., Morris, E., and Vannini, A. (2018). Structural basis of RNA polymerase III transcription initiation. *Nature* 553, 301–306.
 194. Girbig, M., Misiaszek, A.D., Vorländer, M.K., Lafita, A., Grötsch, H., Baudin, F., Bateman, A., and Müller, C.W. (2021). Cryo-EM structures of human RNA polymerase III in its unbound and transcribing states. *Nat. Struct. Mol. Biol.* 28, 210–219.
 195. Vorländer, M.K., Khatter, H., Wetzel, R., Hagen, W.J.H., and Müller, C.W. (2018). Molecular mechanism of promoter opening by RNA polymerase III. *Nature* 553, 295–300.
 196. Kim, Y., Lee, J., Shin, H., Jang, S., Kim, S.C., and Lee, Y. (2017). Biosynthesis of brain cytoplasmic 200 RNA. *Sci. Rep.* 7, 6884.
 197. Booy, E.P., Gussakovsky, D., Brown, M., Shwaluk, R., Nachtigal, M.W., and McKenna, S.A. (2024). lncRNA BC200 is processed into a stable Alu monomer. *RNA (N. Y.)* 30, 1477–1494.
 198. Liu, S., Hua, Y., Wang, J., Li, L., Yuan, J., Zhang, B., Wang, Z., Ji, J., and Kong, D. (2021). RNA polymerase III is required for the repair of DNA double-strand breaks by homologous recombination. *Cell* 184, 1314–1329.e10.
 199. Lim, G., Hwang, S., Yu, K., Kang, J.Y., Kang, C., and Hohng, S. (2023). Translocating RNA polymerase generates R-loops at DNA double-strand breaks without any additional factors. *Nucleic Acids Res.* 51, 9838–9848.
 200. Saur, F., Lesage, E., Pradel, L., Collins, S., Finoux, A.L., Alghoul, E., Le Bozec, B., Rocher, V., Carette, R., Puget, N., et al. (2025). Transcriptional repression facilitates RNA: DNA hybrid accumulation at DNA double-strand breaks. *Nat. Cell Biol.* 27, 992–1005.
 201. Rajendra, K.C., Cheng, R., Zhou, S., Lizarazo, S., Smith, D.J., and Van Bortle, K. (2024). Evidence of RNA polymerase III recruitment and transcription at protein-coding gene promoters. *Mol. Cell* 84, 4111–4124.e4115.
 202. Duttkie, S.H.C. (2014). RNA polymerase III accurately initiates transcription from RNA polymerase II promoters *in vitro*. *J. Biol. Chem.* 289, 20396–20404.
 203. Baux, D., Van Goethem, C., Ardouin, O., Guignard, T., Bergognoux, A., Koenig, M., and Roux, A.-F. (2021). MobiDetails: online DNA variants interpretation. *Eur. J. Hum. Genet.* 29, 356–360.
 204. Freeman, P.J., Hart, R.K., Gretton, L.J., Brookes, A.J., and Dalglish, R. (2018). VariantValidator: Accurate validation, mapping, and formatting of sequence variation descriptions. *Hum. Mutat.* 39, 61–68.
 205. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P., and Cunningham, F. (2016). The Ensembl Variant Effect Predictor. *Genome Biol.* 17, 122.
 206. Stawiński, P., and Płoski, R. (2024). Genebe.net: Implementation and validation of an automatic ACMG variant pathogenicity criteria assignment. *Clin. Genet.* 106, 119–126.
 207. Ng, P.C., and Henikoff, S. (2003). SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res.* 31, 3812–3814. <https://doi.org/10.1093/nar/gkg509>.
 208. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server for predicting damaging missense mutations. *Nat. Methods* 7, 248–249.
 209. Cheng, J., Novati, G., Pan, J., Bycroft, C., Žemgulytė, A., Applebaum, T., Pritzel, A., Wong, L.H., Zielinski, M., Sargeant, T., et al. (2023). Accurate proteome-wide missense variant effect prediction with AlphaMissense. *Science* 381, eadg7492.
 210. Frazer, J., Notin, P., Dias, M., Gomez, A., Min, J.K., Brock, K., Gal, Y., and Marks, D.S. (2021). Disease variant prediction with deep generative models of evolutionary data. *Nature* 599, 91–95.
 211. Jian, X., Boerwinkle, E., and Liu, X. (2014). In silico prediction of splice-altering single nucleotide variants in the human genome. *Nucleic Acids Res.* 42, 13534–13544.

212. Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J.F., Darbandi, S.F., Knowles, D., Li, Y.I., Kosmicki, J.A., Arbelaez, J., Cui, W., Schwartz, G.B., et al. (2019). Predicting Splicing from Primary Sequence with Deep Learning. *Cell* 176, 535–548.e24.
213. Nakamura, Y., Gojobori, T., and Ikemura, T. (2000). Codon usage tabulated from international DNA sequence databases: status for the year 2000. *Nucleic Acids Res.* 28, 292.
214. Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wang, Q., Alföldi, J., Watts, N.A., Vittal, C., Gauthier, L. D., et al. (2024). A genomic mutational constraint map using variation in 76,156 human genomes. *Nature* 625, 92–100.
215. Ramsay, E.P., Abascal-Palacios, G., Daiß, J.L., King, H., Gouge, J., Pilsl, M., Beuron, F., Morris, E., Gunkel, P., Engel, C., and Vannini, A. (2020). Structure of human RNA polymerase III. *Nat. Commun.* 11, 6409.
216. Vos, S.M., Farnung, L., Boehning, M., Wigge, C., Linden, A., Urlaub, H., and Cramer, P. (2018). Structure of activated transcription complex Pol II–DSIF–PAF–SPT6. *Nature* 560, 607–612.
217. Walker-Kopp, N., Jackobel, A.J., Pannafino, G.N., Morocho, P.A., Xu, X., and Knutson, B.A. (2017). Treacher Collins syndrome mutations in *Saccharomyces cerevisiae* destabilize RNA polymerase I and III complex integrity. *Hum. Mol. Genet.* 26, 4290–4300.
218. Noack Watt, K.E., Achilleos, A., Neben, C.L., Merrill, A.E., and Trainor, P.A. (2016). The Roles of RNA Polymerase I and III Subunits Polr1c and Polr1d in Craniofacial Development and in Zebrafish Models of Treacher Collins Syndrome. *PLoS Genet.* 12, e1006187.
219. Misiaszek, A.D., Girbig, M., Grötsch, H., Baudin, F., Murciano, B., Lafita, A., and Müller, C.W. (2021). Cryo-EM structures of human RNA polymerase I. *Nat. Struct. Mol. Biol.* 28, 997–1008.